



CURRICULUM VITAE

Naoto Tada Ueno, M.D., Ph.D., F.A.C.P.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Section Chief, Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Nylene Eckles Distinguished Professorship in Breast Cancer Reserch, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Executive Director, The University of Texas MD Anderson Cancer Center Morgan Welch Inflammatory Breast Cancer Program, Houston, TX

Professor, with Tenure, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

N/A

CITIZENSHIP

[REDACTED]

HOME ADDRESS

[REDACTED]

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: Unit 1354
Houston, TX 77030
Room Number: CPB5.3506
Phone: 713-792-8754
Fax: 713-794-4385

EDUCATION

Degree-Granting Education

Wakayama Medical College, Wakayama, Japan, MD, [REDACTED] Doctor of Medicine

The University of Texas Graduate School of Biomedical Sciences, Houston, TX, PHD [REDACTED],
Cancer Biology

Postgraduate Training

Clinical Internship, Rotating Internship, United States Naval Hospital, Yokosuka, Kanagawa, Japan, [REDACTED]

Clinical Internship, Internal Medicine, Montefiore University Hospital - University of Pittsburgh, Pittsburgh, PA [REDACTED]

Clinical Residency, Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA,
[REDACTED]

Clinical Fellowship, Medical Oncology and Blood and Marrow Transplantation, The University of
Texas MD Anderson Cancer Center, Houston, TX, [REDACTED]

CREDENTIALS

Board Certification

American Board of Internal Medicine - Internal Medicine, [REDACTED], Recertification
Date: [REDACTED]

American Board of Internal Medicine - Medical Oncology, [REDACTED] Recertification
Date: [REDACTED]

Licensures

Active

Japan, [REDACTED]

TX, [REDACTED]

Inactive

N/A

EXPERIENCE/SERVICE

Academic Appointments

Instructor, Department of Hematology, Division of Medicine, The University of Texas M. D.
Anderson Cancer Center, Houston, TX, 1996–1998

Assistant Professor, Stem Cell Transplantation & Cellular Therapy, Division of Cancer Medicine,
The University of Texas MD Anderson Cancer Center, Houston, TX, 1998–2004

Associate Professor, Department of Molecular and Cellular Oncology, Division of Cancer
Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/1999–5/2006

Associate Professor, Stem Cell Transplantation & Cellular Therapy, Division of Cancer Medicine,
The University of Texas MD Anderson Cancer Center, Houston, TX, 2004–2009

Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The
University of Texas MD Anderson Cancer Center, Houston, TX, 2007–2009

Professor, Stem Cell Transplantation & Cellular Therapy, Division of Cancer Medicine, The
University of Texas MD Anderson Cancer Center, Houston, TX, 2009–2011

Professor, with Tenure, Department of Breast Medical Oncology, Division of Cancer Medicine,
The University of Texas MD Anderson Cancer Center, Houston, TX, 2009–present

Administrative Appointments/Responsibilities

Director, The University of Texas M. D. Anderson Cancer Center Breast Cancer Translational
Research Laboratory, Houston, TX, 2002–2004

Executive Director, The University of Texas MD Anderson Cancer Center Morgan Welch
Inflammatory Breast Cancer Program, Houston, TX, 6/2011–present

Section Chief, Section of Translational Breast Cancer Research, Department of Breast Medical
Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,
Houston, TX, 6/2011–present

Other Appointments/Responsibilities

Leader, The University of Texas MD Anderson Cancer Center, SCT Solid Tumor Program,
Houston, TX, 2006–2010

Member, The University of Texas Health Science Center at Houston, Center for Clinical and
Translational Research, Houston, TX, 2007–2009

Board Member of Program Advisory Committee, Cancer Net Japan, Tokyo, Tokyo, Japan, 7/2009–present

Medical Advisor, Inflammatory Breast Cancer Foundation, Milford, MI, 6/2011–present

Endowed Positions

Nylene Eckles Distinguished Professorship in Breast Cancer Reserch, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2012–present

Consultantships

Junai of the Tokyo Hospital Pharmacists Association, Tokyo Japan, Consultant, 2003–present

Japan Comprehensive Cancer Network, Breast, Tokyo, Japan, Board of Directors, 2005–present

Military or Other Governmental Service

U.S. Naval Hospital, Department of Medicine, Civilian, 1989–1990

Institutional Committee Activities

Fellows Education Committee, Member, 1994–1995

M. D. Anderson Associates, Member, 1995–2000

M. D. Anderson Associates, Vice Chair, 2000–2001

Asia Task Force, Member, 2000–2003

BMT in Breast and Kidney Cancer, Dept of Blood and Marrow Transplantation Division of Cancer Medicine, Program Leader, 2000–2006

M. D. Anderson Alumni and Faculty Associates, Chairman, 2001–2009

MD Anderson & St. Luke International Hospital & Keio University Sister Institution Committee, Extramural activity (GAP), Chairman, 2003–present

Japanese International Advisory Committee, Member, 2007–2009

Breast Cancer Bone Metastasis Working Group, Chair, 2007–2011

Breast Medical Oncology Department Concepts & Protocols Review Committee, Committee Chairman, 12/2010–12/2011

Educational Role Recognition Committee, Member, 2011–2012

Global Academic Programs Steering Committee, Member, 8/2012–7/2014

HONORS AND AWARDS

Clinical Fellow Research Award, M. D. Anderson Cancer Center, 1995–1996

Cancer Research Achievement Award, M. D. Anderson Cancer Center, 1996

Houston Endowment, Jesse H. Jones Fellowship in Cancer Education, 1996

Outstanding Achievement in Cancer Research Award, Pharmacia and Upjohn, 1996

American Association Cancer Research-Glaxo Wellcome Oncology Clinical Research Scholar Award for Promising Translation or Clinical Research, Glaxo Wellcome, 1998

5th Annual Robert M. Chamberlain Distinguished Mentor Award Nomination, M. D. Anderson Postdoctoral Association Steering Committee, 2007–2008

6th Robert M. Chamberlain Distinguished Mentor Award Nomination (Finalist top 3), M. D. Anderson, 2008–2009

6th Annual Robert M. Chamberlain Distinguished Mentor Award, M. D. Anderson Postdoctoral Association, 2009

MD Anderson's Distinguished Faculty Mentor Award Nomination, The University of Texas MD Anderson Cancer Center, 2010

MD Anderson Distinguished Faculty Mentoring Award, The University of Texas MD Anderson Cancer Center

RESEARCH

Grants and Contracts (past 5 years)

Funded

Principal Investigator, Cell-cycle profiling of cancer cells to predict chemotherapy response, Sysmex, Research Development Award, Sysmex, 5/12/2003–present, [REDACTED]

Principal Investigator, Development of PEA15 as a therapeutic gene for ovarian cancer, R01CA127562-01, NIH/NCI, 9/1/2007–8/31/2013, [REDACTED]

Principal Investigator, Japan TeamOncology Program, St. Luke Life Science Foundation, 7/1/2008–present, [REDACTED]

Project Member, Education and Research Center for Stem Cell Medicine, GCOE, GCOE Award, 9/1/2008–8/31/2013, [REDACTED]

Principal Investigator, Identification of treatment targets in triple-negative breast cancer by AZD6244 in inhibiting metastasis, LS2009-00267 12LG, AstraZeneca, 12/8/2008–present, [REDACTED]

Co-Investigator, Development of IBC registry, St. Luke Life Science Foundation, PI - Hideoko Yamauchi, 4/3/2009–present, [REDACTED]

Principal Investigator, Development of EGFR Tyrosine Kinase Inhibitor as a Targeted Therapy in Inflammatory Breast Cancer, Susan G. Komen Breast Cancer Foundation, 5/1/2009–4/30/2012, [REDACTED]

Mentor, Development of Targeted therapy for ERK Pathway in Breast Cancer, 1K99CA139006-01A1, NIH/NCI, 9/30/2009–8/31/2014, [REDACTED]

Principal Investigator, Role of AS703026 for modulating EMT in breast cancer with basil-like phenotype and inflammatory breast cancer, LS2010-00031080LG, EMD Serono, Inc., 4/1/2010–present [REDACTED]

Co-Investigator, 2%, A New Radiopharmaceutical for the Treatment of Metastatic Breast Cancer, 1r43ca150601-01A1, NIH/NCI, PI - [REDACTED], 10/1/2010


Principal Investigator, A phase I/II to evaluate the safety, tolerability and preliminary efficacy of KW-2450 in combination with lapatinib and letrozole in subjects with advanced or metastatic breast cancer, CS2011-00034728JW 01, Kyowa Hakko Kirin Co., Ltd., 4/18/2011–4/30/2014, [REDACTED]


Co-Investigator, Immunotherapies for Targeting Ancient Retrovirus During Breast Cancer, BC100340, DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP), 9/30/2011–9/29/2014, \$94,254 (\$31,418/year)

Co-Investigator, Phase I studies or targeted anti-cancer therapies, 5U01CA062461-19, NIH/NCI, PI - [REDACTED] 3/2012–3/2013 (\$436,197/year)

Principal Investigator, My Oncology Dream Award, Lance Armstrong Foundation Award, Lance Armstrong Foundation, 8/1/2012, [REDACTED]


Pending





Other

Principal Investigator, Role of Downstream EGFR Signaling in Erlotinib Sensitivity, Undergoing Renewal Process, R01CA123318-01, NIH/NCI, 6/1/2007-5/31/2012, \$950,000



Completed

Co-Leader, E1A Gene Therapy in Ovarian Cancer - Co-Project #3, Spore, NIH/NCI, PI - [REDACTED] 9/1/1995-1/29/2009, \$1,186,945

Principal Investigator, Adenovirus E1A gene as a chemosensitizer in breast cancer, M. D. Anderson Cancer Center, 3/1/1998-present, [REDACTED]

Principal Investigator, Intravenous administration of E1A complexed with cationic liposome, M. D. Anderson Cancer Center, 8/22/2000-present, [REDACTED]

Collaborator, Development of a patient - health care provider information sharing, multidisciplinary approach to cancer care in Japan., Grants-in-Aid for Scientific Research, 4/1/2003-present, [REDACTED]

Principal Investigator, PEA-15 as a therapeutic target for enhanced sensitization to paclitaxel in metastatic breast cancer, Postdoctoral Award, Susan G. Komen Breast Cancer Foundation, 6/1/2006-5/30/2009, [REDACTED]


Principal Investigator, Role of Mitotic Checkpoint in the sensitivity in breast cancer in paclitaxel, Susan G. Komen Breast Cancer Foundation, 6/1/2006-5/30/2010, [REDACTED]

Principal Investigator, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation with Bevacizumab for Advanced Solid Tumor, CCTS Pilot Project Award, 9/18/2007-9/17/2009, [REDACTED]

Principal Investigator, Academy of Cancer Expert (ACE), AZ46032, AstraZeneca Medical Education Grants Office, 7/1/2008-6/30/2009, [REDACTED]

Co-Investigator, Profiling ER, PR, EGFR and HER2 in Breast Cancer Using Multiplex Tissue Immunostaining, NIH/NCI, 7/1/2008-6/30/2010, \$226,800

Not Funded



Protocols

Funded

Principal Investigator, Multi-Institutional Phase II Study of Combined Herceptin and Paclitaxel after HDCT with Autologous PBPC Transplantation for HER-2/neu Overexpressing Metastatic Breast Cancer, DM99-004, 1999–2005, Genentech

Principal Investigator, Pilot Study of Autologous Transplantation with Immunomodulation of Metastatic Breast Cancer, DM97-323, 1999–2006, Berlex - Immunex

Principal Investigator, Phase II study of combined Herceptin and GM-CSF for Herceptin-Resistant Her-2/neu-overexpressing metastatic breast cancer, DM01-0100, 2002–present, [REDACTED], Berlex

Principal Investigator, Phase II Study of GnRH Analogue For Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients, ID01-710, 2002–present, [REDACTED] TAP Pharmaceutical

Principal Investigator, Phase III randomized study of a goserelin acetate for preservation of ovarian function in patients with primary breast cancer, 2005-0464, 2006–present, [REDACTED] St. Luke Life Science Institute

Principal Investigator, Phase 2 Study of 153 Sm-EDTMP Followed by Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients with Bone Only Metastases, 2006-0349, 2007–present, [REDACTED] Cytogen

Principal Investigator, Phase II study of purging of CTCs from Metastatic Breast Cancer, 2006-0280, 2007–present [REDACTED], Cellerant Therapeutics

Principal Investigator, Phase II Study of Panitumumab, Nab-paclitaxel, and carboplatin for Patients with Primary Inflammatory Breast Cancer (IBC) without HER2 Overexpression, 2008-0372, 2008–present, [REDACTED] Amgen, Abraxis Bio

Principal Investigator, Identification of Treatment Targets in Triple-Negative Breast Cancer by AZD6244 in Inhibiting Metastasis, Animal Protocol - No number, 2009–present, [REDACTED] [REDACTED], AstraZeneca

Unfunded

N/A

Patents and Technology Licenses

Patents

University of Texas System, Board of Regents, Naoto T. Ueno, Mien-Chie Hung. Sensitization of HER-2/NEU Overexpressing Cancer Cells to Chemotherapy, United States, Australia 733737, 9/6/2001, Issued

Sensitization of HER-2/NEU Overexpressing Cancer Cells to Chemotherapy, United States, USA 6395712, 5/28/2002, Issued

Technology Licenses

Systemex Corporation, Taxane Chemosensitivity Prediction Test, 10/926, 409, 4/27/2007

Grant Reviewer/Service on Study Sections

Investigator Initiated Research and Career Catalyst Research, Susan G. Komen Breast Cancer Foundation, Member, BCTR Review, 1998–2005

Reviewer, Associazione Italiana per la Ricerca sul Cancro, Grant Review Committee, Member, 2003–2004

Breast Cancer, Susan G. Komen Breast Cancer Foundation, Reviewer, Targeted Therapy Review Committee, 2006–present

Reviewer, CancerCare Manitoba Foundation, Reviewer, A molecular mechanism of androgen independent prostate cancer through interaction between androgen receptor and HER2/neu., 2008

BMCT, NIH, Ad Hoc Member, 2008–present

AACR Clinical and Translational Cancer Research Fellowships Scientific Review Committee, AACR, Member, 2009–present

Health Sciences Centre Foundation, Canadian Grant Agency, Reviewer, 2010

PUBLICATIONS

Peer-Reviewed Original Research Articles

1. Ueno NT, Zukowski AA. Combination recombinant interleukin-2, recombinant interferon-alpha, and 5-fluorouracil for treatment of metastatic renal cell carcinoma. *J Clin Oncol* 18:358-62, 8/1995.
2. Ueno NT, Kiyokawa N, Hung M. Growth suppression of low HER-2/neu-expressing breast cancer cell line MDA-MB-435 by tyrosine kinase inhibitor emodin. *Oncol Report* 3:509-511, 1996.
3. Ueno NT, Zhao S, Robertson LE, Consoli U, Andreeff M. 2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. *Leukemia* 11(8):1386-90, 8/1997.
4. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. *Oncogene* 15(8):953-60, 8/1997.
5. Ueno NT, Wasaff B, Hortobagyi G, Buzdar A. Combined modality approach for the treatment of inflammatory breast carcinoma: Twenty-year experience of M. D. Anderson Cancer Center. *Cancer Chemoth Pharmacol* 40:321-329, 1997.
6. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralto SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Korbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. *J Clin Oncol* 16(3):986-93, 3/1998.
7. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, Giralto S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno NT, Andersson B, Gee A, Champlin R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. *J Clin Oncol* 16(8):2817-24, 8/1998.
8. Ueno NT, Amato RJ, Ro JJ, Weber RS. Primary malignant teratoma of the thyroid gland: report and discussion of two cases. *Head Neck* 20(7):649-53, 10/1998.
9. Ueno NT, Xia W, Tucker SD, Zhang S, Lopez-Berestein G, Huang L, Hung MC. Issues in the development of gene therapy: preclinical experiments in E1A gene delivery. *Oncol Rep* 6(2):257-62, 3/1999.
10. Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Korbling M, Giralto S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. *Ann Oncol* 10(5):527-32, 5/1999.
11. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, Korbling M, Huh YO, Giralto S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. *Blood* 94(4):1465-70, 8/1999.
12. Champlin R, Khouri I, Kornblau S, Marini F, Anderlini P, Ueno NT, Molldrem J, Giralto S. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. *Hematol Oncol Clin North Am* 13(5):1041-57, vii-viii, 10/1999.

13. Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, Korbling M, Giralt S, Gajewski J, Fischer H, Donato M, Cleary K, Claxton D, Chan KW, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin R. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. *Bone Marrow Transplant* 24(7):763-8, 10/1999.
14. Champlin R, Khouri I, Kornblau S, Marini F, Anderlini P, Ueno NT, Molldrem J, Giralt S. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. *Hematology/Oncology Clinics of North America* 12:1041-1057, 1999.
15. Ueno NT, Hortobagyi GN, Champlin RE. Allogeneic peripheral blood progenitor cell transplantation in solid tumors. *Cancer Treat Res* 101:133-56, 1999.
16. Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Jr, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. *Bone Marrow Transplant* 25(11):1137-40, 6/2000.
17. Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Korbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez, Hagemeister F, McLaughlin P, Cabanillas F, Champlin RE. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. *Bone Marrow Transplantation* 26(6):615-20, 9/2000.
18. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, Ueno N, Giralt S, Anderlini P. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. *Br J Haematol* 111(1):18-29, 10/2000.
19. Hung M, Hortobagyi G, Ueno NT. Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer. *Adv Exp Med Biology* 465:171-180, 2000.
20. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. *Clin Cancer Res* 6(1):250-9, 2000.
21. Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, Khouri IF, Folloder J, Ueno NT, Mehra R, Ippoliti C, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Anderlini P, Andersson BS, Champlin R. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. *Biol Blood Marrow Transplant* 6(2A):190-7, 2000.
22. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. *Blood* 97(3):631-7, 2/2001.
23. Shaikh ZH, Ueno NT, Kontoyiannis DP. Fatal Salmonella group G enteritis mimicking intestinal graft-versus-host disease in a bone marrow transplant recipient. *Transpl Infect Dis* 3(1):29-33, 3/2001.
24. Konoplev S, Champlin RE, Giralt S, Ueno NT, Khouri I, Raad I, Rolston K, Jacobson K, Tarrand J, Luna M, Nguyen Q, Whimbey E. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. *Bone Marrow Transplant* 27:877-881, 4/2001.
25. Shimoni A, Smith TL, Aleman A, Weber D, Dimopoulos M, Anderlini P, Andersson B, Claxton D, Ueno NT, Khouri I, Donato M, Korbling M, Alexanian R, Champlin R, Giralt S. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. *Bone Marrow Transplant* 27(8):821-8, 4/2001.
26. Champlin R, Khouri I, Anderlini P, Gajewski J, Kornblau S, Molldrem J, Shimoni A, Ueno NT, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. *Bone Marrow Transplant* 27 Suppl 2:S13-22, 5/2001.
27. Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno NT, deVos D, Champlin R, Giralt S. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. *Bone Marrow Transplant* 27(12):1221-5, 6/2001.

28. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. *J Clin Oncol* 19(14):3422-33, 7/2001.
29. Ghosh S, Champlin RE, Ueno NT, Anderlini P, Rolston K, Raad I, Kontoyiannis D, Jacobson K, Luna M, Tarrand J, Whimbey E. Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. *Bone Marrow Transplant* 28(3):271-5, 8/2001.
30. Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D. Thiopeta, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. *Am J Hematol* 67(4):227-33, 8/2001.
31. Buchholz TA, Hill BS, Tucker SL, Frye DK, Kuerer HM, Buzdar AU, McNeese MD, Singletary SE, Ueno NT, Pusztai L, Valero V, Hortobagyi GN. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. *Cancer J* 7(5):413-20, 9/2001.
32. Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno NT, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C, Hortobagyi GN. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. *Cancer* 92(7):1775-82, 10/2001.
33. Kim YS, Konoplev SN, Montemurro F, Hoy E, Smith TL, Rondon G, Champlin RE, Sahin AA, Ueno NT. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. *Clin Cancer Res* 7(12):4008-12, 12/2001.
34. Hortobagyi GN, Ueno NT, Hung MC. E1A is an oncogene and may immortalize normal cells, especially in combination with other oncoproteins. *J Clin Oncol* 19:4183-4184, 2001.
35. Ueno NT, Yu D, Hung MC. E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. *Breast Cancer* 8(4):285-93, 2001.
36. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Korbling M, Martin T, Ueno NT, Champlin RE, Khouri IF. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. *Ann Oncol* 13(3):450-9, 3/2002.
37. Montemurro F, Rondon G, Ueno NT, Munsell M, Gajewski JL, Champlin RE. Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. *Bone Marrow Transplant* 29(10):861-6, 5/2002.
38. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno NT, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. *Bone Marrow Transplant* 30(6):367-73, 9/2002.
39. Ueno NT, Anagnostopoulos A, Rondon G, Champlin RE, Mikhailova N, Pankratova OS, Zoubarovskaya LS, Semenova EV, Afanasyev BV, O'Brien S, Andreeff M, Zaritskey AY. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. *Br J Haematol* 119(1):131-4, 10/2002.
40. Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E, Paul R, Li S, Yo GH, Huang L, Hung MC. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. *Cancer Res* 62(22):6712-6, 11/2002.
41. Cheng, YC, Ueno NT. Nonmyeloablative Allogeneic Peripheral Blood Progenitor Cell Transplantation for Metastatic Breast Cancer and Metastatic Renal Cell Carcinoma: The M. D. Anderson Cancer Center Experience. *Haematologica* 87(6):6-9, 2002.
42. Gajewski JL, Rondon G, Donato ML, Anderlini P, Korbling M, Ippoliti C, Benyunes M, Miller LL, LaTemple D, Jones D, Ashby M, Hellmann S, Durett A, Lauppe J, Geisler D, Khouri IF, Giralt SA, Andersson B, Ueno NT, Champlin R. Use of thrombopoietin in combination with chemotherapy and

- granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. *Biol Blood Marrow Transplant* 8(10):550-6, 2002.
43. Montemurro F, Rondon G, Munsell M, Smith TL, Donato ML, Gajewski JL, Rahman ZU, Buzdar AU, Champlin RE, Ueno NT. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. *Biol Blood Marrow Transplant* 9(5):330-40, 5/2003.
 44. Wong R, Rondon G, Saliba RM, Shannon VR, Giralt SA, Champlin RE, Ueno NT. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. *Bone Marrow Transplant* 31(12):1157-63, 6/2003.
 45. Cheng YC, Ueno NT. Allogeneic hematopoietic stem cell transplantation for solid tumors in the United States: a review. *Nippon Rinsho* 61(9):1619-34, 9/2003.
 46. Trent JC, Chamsangavej C, Shah H, Giralt S, Ueno NT. Hepatic haematoma after allogeneic transplantation. *Br J Haematol* 122(5):694, 9/2003.
 47. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. *Blood* 102(10):3829-36, 11/2003.
 48. Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J, Molldrem J, Ueno NT, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. *Biology and current indications. Oncology (Williston Park)* 17(1):94-100; discussion 103-7, 2003.
 49. Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. *Cancer Res* 64(7):2502-8, 4/2004.
 50. Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, Khouri IF. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. *J Clin Oncol* 22(12):2419-23, 6/2004.
 51. Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. *Cancer Res* 64(11):3981-6, 6/2004.
 52. Chiu SJ, Ueno NT, Lee RJ. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. *J Control Release* 97(2):357-69, 6/2004.
 53. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. *J Clin Oncol* 22(14):2942-53, 7/2004.
 54. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno NT, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. *Blood* 104(3):865-72, 8/2004.
 55. Anderlini P, Acholonu SA, Okoroji GJ, Andersson BS, Couriel DR, De Lima MJ, Donato ML, Khouri IF, Giralt SA, Ueno NT, Champlin RE. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. *Bone Marrow Transplant* 34(6):511-4, 9/2004.
 56. Cheng YC, Rondon G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NT. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. *Biol Blood Marrow Transplant* 10(11):794-804, 11/2004.
 57. Sudo T, Ueno NT, Saya H. Functional analysis of APC-Cdh1. *Methods Mol Biol* 281:189-98, 2004.
 58. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. *Biol Blood Marrow Transplant* 11(2):108-14, 2/2005.
 59. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and

- refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. *Bone Marrow Transplantation* 35(10):943-51, 5/2005.
60. Takahashi T, Yamasaki F, Sudo T, Itamochi H, Adachi S, Tamamori-Adachi M, Ueno NT. Cyclin A-associated kinase activity is needed for paclitaxel sensitivity. *Mol Cancer Ther* 4(7):1039-46, 7/2005.
 61. Bartholomeusz C, Itamochi H, Yuan LX, Esteva FJ, Wood CG, Terakawa N, Hung MC, Ueno NT. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. *Cancer Res* 65(18):8406-13, 9/2005.
 62. Cheng YC, Tannir N, Champlin RE, Ueno NT. Allogeneic hematopoietic stem-cell transplantation for metastatic renal cell carcinoma. *Kidney Cancer J* 3:11-20, 2005.
 63. Ueno NT. CNS from a physician's perspective. *Rinsho kango* 31(11):1660-1662, 2005.
 64. Cheng YC, Saliba RM, Rondon G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. *Haematologica* 90:1725-1726, 2005.
 65. Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. *Oncogene* 25(1):79-90, 1/2006.
 66. Ueno NT, Konoplev S, Buchholz TA, Smith T, Rondon G, Anderlini P, Giralt SA, Gajewski JL, Donato ML, Cristofanilli M, Champlin RE. High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. *Bone Marrow Transplant* 37:929-35, 5/2006.
 67. Itamochi H, Yamasaki F, Sudo T, Takahashi T, Bartholomeusz C, Das S, Terakawa N, Ueno NT. Reduction of radiation-induced apoptosis by specific expression of Bcl-2 in normal cells. *Cancer Gene Ther* 13(5):451-9, 5/2006.
 68. Nahta R, Yuan LX, Fiterman DJ, Zhang L, Symmans WF, Ueno NT, Esteva FJ. B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells. *Mol Cancer Ther* 5:1593-601, 6/2006.
 69. Woodward WA, Vinh-Hung V, Ueno NT, Cheng YC, Royce M, Tai P, Vlastos G, Wallace AM, Hortobagyi GN, Nieto Y. Prognostic value of nodal ratios in node-positive breast cancer. *J Clin Oncol* 24:2910-6, 6/2006.
 70. Nakayama K, Ueno NT. American Society of Clinical Oncology recommendations on fertility preservation should be implemented regardless of disease status or previous treatments. *J Clin Oncol* 24(33):5334-5; author reply 5337-8, 11/2006.
 71. Qazilbash MH, Ueno NT, Hosing C, De Lima M, Cortes J, Massaro A, Rivera Z, Deavers M, Adachi JA, Champlin RE. Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation. *Bone Marrow Transplant* 38:393-394, 2006.
 72. Bregni M, Ueno NT, Childs R. The Second International Meeting on Allogeneic Transplantation in Solid Tumors. *Bone Marrow Transplant* 38(8):527-537, 2006.
 73. Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. *Cancer Res* 67(12):5779-88, 6/2007.
 74. Itamochi H, Kigawa J, Kanamori Y, Ueno NT. Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. *Molecular Cancer Therapy* 6:227-235, 2007.
 75. Sugimoto T, Bartholomeusz C, Tari AM, Ueno NT. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. *Breast Cancer Res* 9(4):R41, 2007.
 76. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V. Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. *Clin Breast Cancer* 7(6):471-479, 2007.
 77. Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN. Inflammatory breast cancer (IBC) and patterns of recurrence: Understanding the biology of a unique disease. *Cancer* 110(7):1436-1444, 2007.
 78. Nakayama K, Tannir NM, Liu P, Wathen JK, Cheng YC, Champlin RE, Ueno NT. Natural History of Metastatic Renal Cell Carcinoma in Patients Who Underwent Consultation for Allogeneic

- Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation* 13(8):975-985, 2007.
79. Yamasaki F, Zhang D, Bartholomeusz C, Sudo T, Hortobagyi GN, Kurisu K, Ueno NT. Sensitivity of Breast Cancer Cells to Erlotinib Depends on Cyclin-Dependent Kinase 2 Activity. *Molecular Cancer Therapeutics* 6(8):2168-2177, 2007.
 80. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemester F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. *Hematologica-the Hematology Journal* 93(2):257-64, Jan-Feb, 2/2008.
 81. Nakayama K, Milbourne A, Schover LR, Champlin RE, Ueno NT. Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. *Nature Clinical Practice Oncology* 5(2):78-89, Jan-Feb, 2/2008.
 82. Dawood S, Ueno NT, Cristofanilli M. The medical treatment of inflammatory breast cancer. *Seminars In Oncology* 35(1):64-71, Jan-Feb, 2/2008.
 83. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemester F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. *Blood* 111(12):5530-6, 6/2008.
 84. Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J, Ueno NT. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. *Cancer Res* 68(22):9311-17, 11/2008.
 85. Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. *Molecular Cancer Therapeutics* 7(7):1846-50, 2008.
 86. Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Eifenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser D. Allogeneic Hematopoietic Cell Transplantation for Metastatic Breast Cancer. *Bone Marrow Transplant* 41(6):537-45, Jan-Feb, 2008.
 87. Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K, Hortobagyi GN, Noguchi S, Sakai T, Ishihara H, Ueno NT. Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. *Breast Cancer Res* 11(1):R12. e-Pub 2/2009.
 88. De Giorgi U, Valero V, Rohren E, Dawood S, Ueno NT, Miller MC, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Fritsche HA, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating Tumor Cells and [18 F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer. *J Clin Oncol* 27(27):1-9. e-Pub 5/2009.
 89. Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT. Molecular targets for treatment of inflammatory breast cancer. *Nat Rev Clin Oncol* 6(7):387-94. e-Pub 5/2009.
 90. de Souza JA, Davis ML, Rondon G, Cheng YC, Jones RB, Champlin RE, Ueno NT. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. *Bone Marrow Transplant* 44(2):81-7. e-Pub 5/2009.
 91. Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, Lewis VO, Ma J, Stafford RJ, Tari AM, Hortobagyi GN, Ueno NT. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. *Lancet Oncol* 10(6):606-14, 6/2009.
 92. Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A Novel hTERT Promoter-driven E1A Therapeutic for Ovarian Cancer. *Molecular Cancer Therapeutics* Aug 8(8)(8):2375-82, 8/2009. e-Pub 8/2009. PMID: PMC2759534.
 93. Kai K, Nagano O, Sugihara E, Arima Y, Sampetean O, Ishimoto T, Nakanishi M, Ueno NT, Iwase H, Saya H. Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. *Cancer Sci*, 8/2009. e-Pub 8/2009.

94. Ueno NT, de Souza JA, Booser D, Nakayama K, Madewell J, Wendt RE, Hortobagyi GN, Podoloff D, Champlin RE. Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer. *Clin Breast Cancer* 9(3):173-7, 8/2009.
95. Mego M, De Giorgi U, Hsu L, Ueno NT, Valero V, Jackson S, Andreopoulou E, Kau SW, Reuben JM, Cristofanilli M. Circulating tumor cells in metastatic inflammatory breast cancer. *Ann Oncol* 20(11):1824-8, 11/2009. e-Pub 6/2009.
96. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. *Clin Cancer Res* 15(21):6639-48, 11/2009. e-Pub 10/2009. PMID: PMC2783487.
97. Nakayama K, Liu P, Detry M, Schover LR, Milbourne A, Neumann J, Rondon G, Thewes B, Champlin RE, Ueno NT. Receiving information on fertility- and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation: changes in perceived importance over time. *Biol Blood Marrow Transplant* 15(11):1465-74, 11/2009.
98. Cheng YC, Rondón G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giral SA, Champlin RE, Ueno NT. Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. *Int J Hematol* 90(5):627-34, 12/2009. e-Pub 12/2009.
99. Vinh-Hung V, Nguyen NP, Cserni G, Truong P, Woodward W, Verkooijen HM, Promish D, Ueno NT, Tai P, Nieto Y, Joseph S, Janni W, Vicini F, Royce M, Storme G, Wallace AM, Vlastos G, Bouchardy C, Hortobagyi GN. Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. *Future Oncol* 5(10):1585-603, 12/2009.
100. Yamauchi H, LaFortue T, Ueno NT. Lapatinib in the Treatment of Breast Cancer. *Clinical Medicine: Therapeutics* 1(1):513-526, http://www.la-press.com/article.php?article_id=1498, 2009.
101. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM, Anderson ML, Matzuk MM. A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer. *Mol Endocrinol*. e-Pub 1/2010.
102. De Giorgi U, Valero V, Rohren E, Mego M, Doyle GV, Miller MC, Ueno NT, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. *Ann Oncol* 21(1):33-9, 1/2010. e-Pub 7/2009.
103. Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R, Theriault RL, Hortobagyi GN, Ueno NT. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. *Br J Cancer* 102(4):651-7, 2/2010. e-Pub 1/2010.
104. Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M, Woodward WA. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. *Int J Radiat Oncol Biol Phys* 76(3):889-95, 3/2010.
105. Imamura CK, Takebe N, Nakamura S, Saya H, Ueno NT. Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan. *Nat Rev Clin Oncol* 7(3):127-8, 3/2010.
106. Sugiyama N, Takashima A, Hashimoto H, Osato Y, Kitayama S, Sato H, Ueno NT. Introducing Multidisciplinary Team Practice— Through Our Experience Gained from Visiting MD Anderson Cancer Center. *Jpn J Cancer Chemother* 37:753-757, 3/2010.
107. Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. *Clin Cancer Res* 16(6):1802-11, 3/2010. e-Pub 3/2010.
108. Reuben JM, Lee BN, Li C, Gao H, Broglio KR, Valero V, Jackson SA, Ueno NT, Krishnamurthy S, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. *Breast J* 16(3):327-30, May-Jun, 5/2010. e-Pub 4/2010.
109. Watanabe Y, Yamasaki F, Kajiwara Y, Saito T, Nishimoto T, Bartholomeusz C, Ueno NT, Sugiyama K, Kurisu K. Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic

- tumors: a novel approach of correlating malignancy grade and prognosis. *J Neurooncol.* e-Pub 5/2010.
110. Akar U, Ozpolat B, Mehta K, Lopez-Berestein G, Zhang D, Ueno NT, Hortobagyi GN, Arun B. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. *Mol Cancer Ther* 9(5):1180-7, 5/2010. e-Pub 4/2010.
 111. Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. *Int J Cancer* 1:80-92, 6/2010.
 112. Yamauchi H, Ueno NT. Targeted Therapy in Inflammatory Breast Cancer. *Cancer* 116(S11):2758-2759, 6/2010.
 113. De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG PET/CT Findings and Circulating Tumor Cell Counts in the Monitoring of Systemic Therapies for Bone Metastases from Breast Cancer. *J Nucl Med.* e-Pub 7/2010.
 114. Cheng YC, Ueno NT. Is high-dose chemotherapy with autologous hematopoietic stem cell transplantation in breast cancer patients a done deal? *Womens Health (Lond Engl)* 6(4):481-5, 7/2010.
 115. Hamaoka T, Costelloe CM, Madewell JE, Liu P, Hortobagyi GN, Ueno NT. Reply: Assessment of therapeutic response in patients with metastatic skeletal disease: suggested modifications for the MDA response classification criteria. *Br J Cancer.* e-Pub 7/2010.
 116. Ueno NT, Ito TD, Grigsby RK, Black MV, Apte J. ABC conceptual model of effective multidisciplinary cancer care. *Nat Rev Clin Oncol* 7(9):544-7, 9/2010. e-Pub 7/2010.
 117. Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT. Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. *Br J Cancer* 103(9):1331-4, 10/2010. e-Pub 9/2010. PMID: PMC2990606.
 118. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. *Cancer.* e-Pub 11/2010.
 119. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT. Future directions of bone-targeted therapy for metastatic breast cancer. *Nat Rev Clin Oncol* 7(11):641-51, 11/2010. e-Pub 8/2010.
 120. Zhang D, Tari AM, Akar U, Arun BK, LaFortune TA, Nieves-Alicea R, Hortobagyi GN, Ueno NT. Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser^{1°} p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer. *Mol Cancer Ther* 9(11):3090-9, 11/2010. e-Pub 11/2010.
 121. Dawood S, Ueno NT, Valero V, Andreopoulou E, Hsu L, Lara J, Woodward W, Buchholz TA, Hortobagyi GN, Cristofanilli M. Incidence of and survival following brain metastases among women with inflammatory breast cancer. *Ann Oncol* 21(12):2348-55, 12/2010. e-Pub 5/2010.
 122. Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, Rodriguez AA, Landis MD, Lucci A, Ueno NT, Robertson F, Xu W, Lacerda L, Buchholz TA, Cristofanilli M, Reuben JM, Lewis MT, Woodward WA. Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. *Mol Cancer* 9:180, 2010. e-Pub 7/2010. PMID: PMC2915978.
 123. Niikura N, Ueno NT. The Role of F-FDG-Positron Emission Tomography/Computed Tomography in Staging Primary Breast Cancer. *J Cancer* 1:51-3, 2010. e-Pub 6/2010. PMID: PMC2931351.
 124. Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, Ueno NT, Theriault RL. Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis. *Oncologist* 16(2):155-64, 1/2011.
 125. Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. *Breast Cancer Res Treat* 125(3):785-95, 2/2011.
 126. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. *Ann Oncol* 22(3):515-23, 3/2011. e-Pub 7/2010.
 127. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M,

- Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. *JAMA* 305(18):1873-81, 5/2011.
128. Cheng YC, Ueno NT. Improvement of survival and prospect of cure in patients with metastatic breast cancer. *Breast Cancer*, 5/2011.
 129. Niikura N, Liu J, Costelloe CM, Palla SL, Madewell JE, Hayashi N, Yu TK, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT. Initial Staging Impact of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Locally Advanced Breast Cancer. *Oncologist* 16(6):772-82, 5/2011.
 130. Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. *Breast Cancer Res* 13(3):R67, 6/2011. PMID: PMC3218956.
 131. Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Ferrer-Lozano J, Lluch A, Niikura N, Bartholomeusz C, Nakamura S, Hortobagyi GN, Ueno NT. Prognostic Impact of Phosphorylated HER-2 in HER-2+ Primary Breast Cancer. *Oncologist* 16(7):956-65, 6/2011.
 132. Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. *Int J Clin Oncol*, 6/2011.
 133. Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. *Int J Cancer* 129(2):417-23, 7/2011.
 134. Imamura CK, Ueno NT. Health services: How can we address cancer care after a natural disaster? *Nat Rev Clin Oncol* 8(7):387-8, 7/2011. e-Pub 6/2011.
 135. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Identifying factors that impact survival among women with inflammatory breast cancer. *Ann Oncol*, 7/2011.
 136. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M, Stadtmauer EA, Biron P, Crown JP, Schmid P, Lotz JP, Rosti G, Bregni M, Demirer T. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. *J Clin Oncol* 29(24):3224-31, 8/2011.
 137. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Bassler RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. *J Clin Oncol* 29(24):3214-23, 8/2011. e-Pub.
 138. Itamochi H, Yoshida T, Walker CL, Bartholomeusz C, Aoki D, Ishihara H, Suzuki N, Kigawa J, Terakawa N, Ueno NT. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: Cytoplasmic sequestration of CDK2 by p27. *Gynecol Oncol* 122(3):641-7, 9/2011.
 139. Hayashi N, Nakamura S, Yagata H, Shimoda Y, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. *Int J Clin Oncol* 16(5):596-600, 10/2011.
 140. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. *Ann Oncol*, 10/2011.
 141. Komatsu H, Nakayama K, Togari T, Suzuki K, Hayashi N, Murakami Y, Iioka Y, Osaka W, Yagasaki K, Nakamura S, Neumann J, Ueno NT. Information sharing and case conference among the multidisciplinary team improve patients' perceptions of care. *Open Nurs J* 5:79-85, 10/2011. PMID: PMC3227867.
 142. Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. *Cancer* 117(24):5476-84, 12/2011.

143. Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, Ueno NT, Theriault RL. Retrospective analysis of anti tumor effects of zoledronic acid in breast cancer patients with bone-only metastases. *Cancer*, 12/2011.
144. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. *Oncologist*, 12/2011.
145. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS, Jones R, Popat UR, Hosing CM, Nieto Y, Qazilbash MH, Ueno NT, Giral SA, de Lima MJ, Champlin RE. Donor leukocyte infusions (DLIs) in recurrent hodgkin lymphoma (HL) following allogeneic stem cell transplantation: ten-year experience at the M.D. anderson cancer center. *Leuk Lymphoma*. e-Pub 1/2012.
146. Cheng YC, Takagi M, Milbourne A, Champlin RE, Ueno NT. Phase II Study of Gonadotropin-Releasing Hormone Analog for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients. *Oncologist*, 1/2012.
147. Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, Alvarez RH, Lucci A, Ueno NT, Buchholz TA. Pretreatment Staging Positron Emission Tomography/Computed Tomography in Patients With Inflammatory Breast Cancer Influences Radiation Treatment Field Designs. *Int J Radiat Oncol Biol Phys*. e-Pub 1/2012.
148. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT. Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors. *J Clin Oncol* 30(6):593-9, 2/2012. e-Pub 11/2011. PMID: PMC3295557.
149. Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K, Kazansky A, Krishnamurthy S, Lee J, Esteva FJ, Kigawa J, Ueno NT. MEK 1/2 Inhibitor selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15-dependent Manner in a Mouse Xenograft Model. *Mol Cancer Ther* 11(2):360-9, 2/2012. e-Pub 12/2011.
150. Hayashi N, Nakamura S, Tokuda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Serum HER2 levels determined by two methods in patients with metastatic breast cancer. *Int J Clin Oncol* 17(1):55-62, 2/2012. e-Pub 5/2011.
151. RI A, K S, Nt U, S K, W W, R el-Z, Am B. Epidemiological risk factors associated with inflammatory breast cancer triple negative subtype. *Cancer Epidemiol Biomarkers Prev* 21(3):564, 3/2012. e-Pub 2/2012.
152. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Yang EJ, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. *J Clin Oncol* 30(7):729-34, 3/2012. e-Pub 1/2012.
153. Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobagyi GN, Ueno NT. Inflammatory Breast Cancer: What We Know and What We Need to Learn. *Oncologist*. e-Pub 5/2012.

(b) (6)

Invited Articles

1. Ueno NT, Champlin R. Allogeneic transplantation in metastatic breast cancer; rationale for use of nonmyeloablative preparative regimens. *Seminars in Breast Cancer* 3:176, 2000.
2. Ueno NT. Allogeneic transplantation in solid tumor. *Rinsyoui* 27:48-54, 2001.
3. Ueno NT, Cheng YC. Review of conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem cell transplantation in high-risk breast cancer. *J Clin Oncol*, 2004.
4. Nakayama K, Ueno NT. American Society of Clin Oncol recommendations on fertility preservation should be implemented regardless of disease status or previous treatments. *J Clin Oncol* 24:5334-5335, 2006.
5. Ueno, NT. Profiles in Oncology Social Media. *Oncology Times* 32(10), May 25, 2010. e-Pub 4/2010.

Editorials

1. Ueno NT, Cheng YC, Shpall EJ, Champlin RE. Autologous Hematopoietic Stem Cell Transplantation in Breast Cancer: New Hope. *Breast Disease* 15, 2004.
2. Ueno NT, Shpall EJ, Champlin RE, Jones, RB. Graft-vs-Breast Cancer Effect by Allogeneic Hematopoietic Stem Cell Transplantation: A Possible New Frontier. *J Clin Oncol* 22:3846-3847, 2004.

3. Ueno NT, Cheng YC. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. *Breast Disease* 15:76, 2004.
4. Nakayama K, Ueno NT. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. *Breast Disease* 16, 2005.
5. Ueno NT, Cheng YC. The future of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma in the era of target-specific therapy. *Bone Marrow Transplant* 38:711-771, 2006.
6. Ueno NT, Child RQ. What's past is prologue: lessons learned and the need for further development of allogeneic hematopoietic stem cell transplantation for renal cell carcinoma. *Biology of Blood and Marrow Transplantation* 13:31-33, 2007.

Other Articles

1. Ueno NT. River next to Pittsburgh. *Medical Student* 3(6):123-129, 1993.
2. Ueno NT. River next to Pittsburgh. *Medical Student* 2(6):119-123, 1993.
3. Ueno NT. Cancer Treatment at The University of Texas M. D. Anderson Cancer Center. *Gulf Stream Japan Business Association of Houston Newsletter* 27, 2002.
4. Childs R, Mason J, Ueno NT, . Stem Cell Transplants for Patients with Kidney Cancer. *Blood and Marrow Transplant Newsletter* 13(56), 2002.
5. Ueno NT. Road to Medical Oncologist. *Kani* 30:47-51, 2003.
6. Ueno NT. Importance of Nursing Research. *Nursing Today* 19(6):62-63, 11/2004.
7. Ueno NT. Importance of obtaining consensus among medical staff. *Nursing Today* 19(5):66-67, 2004.
8. Ueno NT. Multi-disciplinary care expands the role of nurses. *Nursing Today* 19(8):64-65, 2004.
9. Ueno NT. Role of advanced nurse practitioners and research nurses. *Nursing Today* 19(7):58-59, 2004.
10. Ueno NT. The role of transplantation in metastatic breast cancer. *Clinical Issues & Therapeutic Advances. USA*:4-5, 2004.
11. Ueno NT. How to receive ultimate medical care. Patient is the most important player. *Nami* 31:338-339, 2007.
12. Ueno NT. Role of clinical pharmacist in cancer care. *Nursing Today* 20, 2007.
13. Ueno, NT. M. D. Anderson Cancer Center Medical Exchange Program. *Oncology*:1-7, 2008.
14. Ueno, NT. More Evidence Is Needed: Perspective from a Frustrated Cancer Doctor/Researcher/Patient. *Oncology Times* 31(22):4-6, 11/2009.
15. Ueno NT. Targeting the Epithelial-mesenchymal Transition to Reduce Metastasis of Inflammatory Breast Cancer. *Breast Cancer Symposium Proceeding*, 9/2010.

Abstracts (past 5 years)

1. Reuben JM, Gao H, Cohen EN, Lee BN, Li C, Lucci A, Krishnamurthy S, Woodward W, Ueno NT, Hortobagyi GN, Cristofanilli M. Circulating tumor cells and metastasis breast cancer: new insights for personalized therapy. Plenary 11. Novel Cellular Markers for cancer progression. 7th Euroconference on Clinical Cell Analysis Rotterdam, The Netherlands, 9/2007.
2. Kim S, Masuda N, Inaji H, Yoshidome K, Tsujimoto M, Akiyama F, Ishihara H, Hortobagyi GN, Ueno NT, Noguchi S. CDK2 and CDK1 specific activities: A novel prognostic indicator in early breast cancer. 2007 ASCO Annual Meeting 25(18S) (#10592), 2007.
3. de Souza JA, Wei C, Noguchi S, Lu K, Ishihara H, Aoki D, Ueno NT. Cyclin-dependent kinase (CDK) activity as a prognostic marker in primary epithelial ovarian cancer. *Proc Annu Meet Soc Clin Oncol* 25:18S (#5575), 2007.
4. Reuben JM, Lee BN, Li C, Broglio KR, Valero V, Jackson S, Ueno NT, Krishnamurthy S, Hortobagyi GN, Cristofanilli M. Genomic of circulating tumor cells in metastatic breast cancer. *J Clin Onco Part I* 25:18S (#1002), 2007.
5. Ueno NT, Kim S, Symmans WF, Detry MA, Pusztai L, Sanchez LF, Ishihara H, Hortobagyi GN, Noguchi S. Prospective study of changes in spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes. *Proc Annual Meeting Am Soc Clin Oncol* 25(18S) (#586), 2007.
6. Ueno NT, Kim S, Symmans WF, Pusztai L, Sanchez LF, Davis M, Ishihara H, Hortobagyi GN, Noguchi S. Prospective study of spindle assembly checkpoint (SAC) to predict breast tumor response to taxanes. 2007 Breast Cancer Symposium:58 (#58), 2007.
7. Zhang D, Pal A, Bornmann W, Esteva F, Hortobagyi G, Ueno NT. Lapatinib activity is independent of EGFR expression levels in HER2-overexpressing breast cancer cells. *Proc Annu Meet Am Assoc Cancer Res* (#4855). e-Pub 4/2008.

8. Cataldo VD, Wang X, Champlin RE, Ueno NT. Hyperglycemia in stem cell transplant recipients: a modifiable risk factor for infection. Proc Annu Meet Soc Clin Oncol (#9605), 2008.
9. Bartholomuesz C, Rosen D, Wei C, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J, Ueno NT. Novel ERK regulator phosphoprotein "PEA-15," which induces Autophagy in Human Ovarian Cancer Cells, is Associated with Prolonged Overall Survival in Women with Primary Epithelial Ovarian Cancer. Proc Annu Meet Assoc Cancer Res. e-Pub 2008.
10. Yamasaki F, Inoue N, Sudo T, Zhang D, Bartholomuesz C, Kurisu K, Hortobagyi GN, Ueno NT. Testis-related gene, MORC1, induces dysfunctional spindle assembly checkpoint, rendering paclitaxel resistance. Proc Annu Meet Am Assoc Cancer Res, 2008.
11. Cristofanilli M, De Giorgi U, Rohren E, Ueno NT, Miller C, Doyle GV, Jackson S, Andreopoulou E, Handy BC, Reuben JM, Hortobagyi GN, Macapinlac HA, Fritsche HA, Valero V. Circulating tumor cells and FDG-PET/CT: biological and functional methods for therapeutic monitoring in metastatic breast cancer. Cancer Res 2009 69 (Suppl.): (2) (#6052 - SABCS), 1/2009.
12. Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Bregni M, Demirer T, MDACC-EBMT Meta-analysis Group. High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 6 randomized metastatic breast cancer trials. Cancer Res 2009 69 (Suppl.): (2) (#6113, SABCS), 1/2009.
13. Lee BN, Li C, Lucci A, Cohen EN, Gao H, Krishnamurthy S, Ueno NT, Hortobagyi GN, Cristofanilli M, Woodward WA, Reuben JM. Notch-1 expression is not related to the percentage of CD326+ cells in bone marrow aspirates of patients with primary breast cancer. Cancer Res 2009 69 (Suppl.): (2) (#4030, SABCS), 1/2009.
14. Hall CS, Debeb BG, Xu W, Ueno NT, Reuben JM, Robertson F, Lucci A, Buchholz TA, Hortobagyi GN, Cristofanilli M, Woodward WA. Novel inflammatory breast cancer cell line, MDA-IBC-1 expresses and secretes WISP3, a putative tumor suppressor in inflammatory breast cancer. Cancer Res 2009 69 (Suppl.): (2):Abstract 1051 (SABCS) (#1051, SABCS), 1/2009.
15. Debeb BG, Hall CS, XU W, Ueno NT, Reuben JM, Robertson F, Lucci A, Buchholz TA, Hortobagyi GN, Cristofanilli M, Woodward WA. Populations of cells exhibiting epithelial-mesenchymal transition (EMT) or stem cell characteristics can be propagated from a single inflammatory breast cancer (IBC) cell line based on culture conditions. Cancer Res 2009 69 (Suppl): (2) (#103, SABCS), 1/2009.
16. Gao H, Lucci A, Cohen EN, Lee B-N, Li C, Krishnamurthy S, Ueno NT, Andreopoulou E, De Giorgi UF, Hortobagyi GN, Cristofanilli M, Woodward W, Reuben JM. Primary tumor size is associated with ALDH breast cancer initiating stem cells in bone marrow aspirates of primary breast cancer patients. Cancer Res 2009 69 (Suppl.): (2) (#4031, SABCS), 1/2009.
17. Kim SJ, Taguchi T, Tamaki Y, Tsukamoto F, Akazawa K, Ueno NT, Hortobagyi GN, Nakayama S, Torikoshi Y, Gohda K, Ishihara H, Noguchi S. Ratio of cyclin-dependent kinase 1 (CDK1) activity to CDK2 activity after ex vivo paclitaxel treatment predicts response to paclitaxel in human breast cancer. Cancer Res 2009 69 (Suppl.): (2) (#6065, SABCS), 1/2009.
18. Robertson FM, Simeone A-M, Lucci A, Woodward W, Reuben J, Ueno NT, Cristofanilli M. Role of prostaglandin receptor EP3 in regulating vasculogenic mimicry of inflammatory breast cancer. Cancer Res 2009 69 (Suppl.): (2) (#2127, SABCS), Cancer Res 2009, 1/2009.
19. Ueno NT, Kazansky A, LaFortune TA, Lucci A, Krishnamurthy S, Hung M-C, Hortobagyi GN, Woodward W, Reuben JM, Robertson F, Cristofanilli M, Zhang D. Suppression of mesenchymal phenotype in inflammatory breast cancer by EGFR tyrosine kinase inhibitor erlotinib: a novel approach to suppressing metastasis. Cancer Res 2009 69 (Suppl.): (2) (#2042, SABCS), 1/2009.
20. Yamauchi H, Nakamura S, Zhang D, Hortobagyi GN, Cristofanilli M, Ueno NT. Potential of molecular targeted therapy for inflammatory breast cancer. Proceeding of Annual Congress of Japan Surgical Association, 11/2009.
21. Lil C, Lee B-N, Woodward WA, Ueno NT, Robertson F, Reuben JM, Cristofanilli M. p53 Mutation in Inflammatory Breast Cancer Cell Lines. 32nd Annual San Antonio Breast Cancer Symposium (#3161), 12/2009.
22. Mego M, Dawood S, De Giorgi U, Valero V, Andreopoulou E, Handy BC, Ueno NT, Reuben JM, Cristofanilli M. Characterization of Metastatic Breast Cancer Patients with Non-Detectable Circulating Tumor Cells. 32nd Annual San Antonio Breast Cancer Symposium (#3006), 2009.
23. De Giorgi U, Mego M, Ueno NT, Handy BC, Jackson S, Reuben JM, Valero V, Cristofanilli M. Effect of Trastuzumab and Chemotherapy on Circulating Tumor Cells in Patients with Poor Prognosis Metastatic Breast Cancer. 32nd Annual San Antonio Breast Cancer Symposium (#3014), 2009.

24. Ueno NT, LaFortune TA, Hortobagyi GN, Cristofanilli M, Lucci A, Singh B, Krishnamurthy S, Esteva FJ, Hung MC, Zhang D. EGFR tyrosine kinase inhibitor erlotinib exhibits antimetastatic activity against inflammatory breast cancer. 2009 Proc Annual Am Assc for Cancer Res (#1767), 2009.
25. Oishi T, Bartholomeusz C, LaFortune T, Zhang D, Kazansky A, Itamochi H, Ueno NT. ERK-binding protein PEA-15 modulates ERK-targeted therapy in ovarian clear cell carcinoma. 2009 Proc Annual Am Assc for Cancer Res (#3702), 2009.
26. Bartholomeusz C, Krishnamurthy S, Yuan LXH, Yamasaki F, Kazansky A, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. PEA-15 inhibits tumorigenesis in a breast cancer xenograft model by inhibiting tumor cell proliferation through increased cytoplasmic localization of activated ERK. 2009 Proc Annual Am Assc for Cancer Res (#2050), 2009.
27. Mego M, De Giorgi U, Hsu L, Dawood S, Andreopoulou E, Valero V, Handy BC, Ueno NT, Reuben JM, Cristofanilli. Predictive Value of Circulating Tumor Cells (CTC's) in Metastatic Breast Cancer Patients Treated by Bevacizumab-Based Therapy. 32nd Annual San Antonio Breast Cancer Symposium (#3013), 2009.
28. LaFortune TA, Ordentlich P, Zhang D, Hortobagyi GN, Cristofanilli M, Ueno NT. Synergistic Effect of Lapatinib and the Class 1 HDAC Inhibitor SNDX-275 in Breast Cancer. 32nd Annual San Antonio Breast Cancer Symposium (#3135), 2009.
29. Zhang D, Hortobagyi GN, Ueno NT. Therapeutic potential of combining an epidermal growth factor receptor tyrosine kinase inhibitor with inhibition of Serine 10 p27 phosphorylation in breast cancer. 2009 Proc Annual Am Assc for Cancer Res (#2773), 2009.
30. Ueno NT, Hortobagyi GN, Cristofanilli M, Zhang D. Role of EGFR Pathway Regulation in EMT of Inflammatory Breast Cancer. AACR Special Conference for EMT, 2/2010.
31. Oishi T, Bartholomeusz C, Kazansky A, Akar U, Krishnamurthy S, Esteva FJ, Itamochi H, Ueno NT. ERK-targeted therapy suppresses tumorigenicity in ovarian clear cell carcinoma and is modulated by ERD-binding protein PEA-15. 101st AACR Annual Meeting Proceedings 51 (#1619), 4/2010.
32. Kai K, Saya H, Hortobagyi GN, Ueno NT. Genetically induced cancer stem cells (CSCs) in mouse mammary gland from Ink4a/Arf-knockout mammary cells transduced with H-rasG12V. 101st AACR Annual Meeting Proceedings 51 (#2458), 4/2010.
33. Bartholomeusz C, Gonzalez-Angulo A, Liu P, Hayashi N, Hortobagyi GN, Ueno NT. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer. 101st AACR Annual Meeting Proceedings 51 (#3140), 4/2010.
34. Cohen EN, Gao H, Bang-Ning L, Andreopoulou E, Jackson SA, Parker CA, Tin S, Galland MM, Ueno NT. Innate immune profile of inflammatory breast cancer patients. 101st AACR Annual Meeting Proceedings 51 (#5583), 4/2010.
35. Zhang D, Tari AM, Akar U, Arun BK, LaFortune TA, Nieves-Alicea R, Hortobagyi GN, Ueno NT. Silencing kinase interacting stathmin gene enhances erlotinib sensitivity by inhibiting serine 10 p27 phosphorylation in EGFR-expressing breast cancer. 101st AACR Annual Meeting Proceedings 51 (#1972), 4/2010.
36. Gao H, Cohen EV, Bang-Ning L, Andreopoulou E, Jackson SA, Parker CA, Tin S, Galland MM, Ueno NT. T-cell cytokine production profile of breast cancer patients. 101st AACR Annual Meeting Proceedings 51 (#5589), 4/2010.
37. Hayashi N, Iwamoto T, Gonzalez-Angulo AM, Niikura N, Nakamura S, Hortobagyi GN, Ueno NT. Phosphorylated-HER2 associated with relapse in patients with HER2-positive breast cancer using reverse phase protein array. 2010 Breast Cancer Symposium Proceeding, 9/2010.
38. Niikura N, Costelloe C, Madewell JE, Hayashi N, Yu TK, Liu J, Palla SL, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT. Role of FDG-PET/CT in Metastatic Staging of Newly Diagnosed Primary Breast Cancer. 2010 Breast Cancer Symposium Proceedings, 9/2010.
39. Van Laere S, Ueno NT. An integrated analysis of three distinct IBC/non-IBC affymetrix gene expression data sets to study transcriptional heterogeneity both between IBC and non-IBC and within IBC only. 2nd International Inflammatory Breast Cancer Conference, 10/2010.
40. Niikura N, Costelloe C, Madewell JE, Hayashi N, Yu TK, Liu J, Palla SL, Tokuda Y, Theriault RL, Hortobagyi GN, Ueno NT. Role of FDG-PET/CT in Metastatic Staging of Newly Diagnosed Primary Inflammatory Breast Cancer. 2nd International Inflammatory Breast Cancer Conference, 10/2010.
41. Simon J, Frank R, Crump, D, Rogers J, Phillips S, Ellebracht S, Ueno N, Wendt III R. Preclinical evaluation of Sm-153-DOTMP as a therapeutic bone-seeking radiopharmaceutical. The Journal of Nuclear Medicine (#1751), 2010.

42. Wang X, Saso H, Iwamoto T, Pusztai L, Gong Y, Woodward WA, Reuben JM, Hortobagyi GN, Ueno NT. A Novel Inflammatory Breast Cancer-Specific Oncogene, Tazarotene-Induced Gene 1, Promotes Tumorigenicity and Invasiveness through the Receptor Tyrosine Kinase Axl. 34th Annual San Antonio Breast Cancer Symposium 71(24):255s (#P2-02-01), 12/2011.
43. Van Laere SJ, Ueno NT, Finetti P, Vermeulen PB, Lucci A, Birnbaum D, Robertson FM, van Dam PA, Woodward WA, Viens P, Dirix LY, Reuben JM, Iwamoto T, Cristofanilli M, Bertucci F. An Integrated Analysis of Three Distinct IBC/nIBC Affymetrix Gene Expression Data Sets Further Unveils the Molecular Biology of IBC. 34th Annual San Antonio Breast Cancer Symposium 71(24):124s (#PD03-01), December 15, 2011, 12/2011.
44. Gao H, Cohen EN, Lee B-N, Giordano A, Tin S, Anfossi S, Parker CA, Cristofanilli M, Valero V, Alvarez RH, Hortobagyi GN, Woodward WA, Ueno NT, Reuben JM. Cytokine Synthesis by Activated Dendritic Cells in Relation to Disease Progression in Inflammatory Breast Cancer (IBC). 34th Annual San Antonio Breast Cancer Symposium 71(24):511s (#P4-20-04), 12/2011.
45. Giordano A, Cohen EN, Anfossi S, Gao H, Lee B-N, Mego M, Sanda T, Valero V, Alvarez RH, Cristofanilli M, De Placido S, Hortobagyi GN, Woodward W, Ueno NT, Reuben JM. Epithelial-Mesenchymal Transition Correlated with Serum Cytokine Profiling in Breast Cancer Patients. 34th Annual San Antonio Breast Cancer Symposium 71(24):164s (#P1-02-07), 12/15/2011, 12/2011.
46. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, Matsuoka J, Hortobagyi GN, Hatzis C, Symmans WF, Pusztai L. Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1%-10% ER-Positive by Immunohistochemistry. 34th Annual San Antonio Breast Cancer Symposium 71(24):191s (#P1-07-09), 12/2011.
47. Anfossi S, Giordano A, Cohen EN, Gao H, Cristofanilli M, Valero V, Alvarez RH, Hortobagyi GN, Woodward W, Ueno NT, Lee B-N, Reuben JM. Higher Expression Levels of Circulating miR-21, miR-19a and miR-10b Are Associated with High Risk Features in Breast Cancer. 34th Annual San Antonio Breast Cancer Symposium 71(24):342s (#P3-03-02), 12/2011.
48. Van Laere SJ, Van Golen KL, Joglekar M, Ueno NT, Finetti P, Van Dam PA, Viens P, Birnbaum D, Bertucci F, Vermeulen PB, Dirix LY. Identification, Validation and Assessment of Transcriptional Relevance of a PDGFR-Activation Signature in (Inflammatory) Breast Cancer. 34th Annual San Antonio Breast Cancer Symposium 71(24):512s (#P5-01-01), 12/2011.
49. Kawai M, Torikoshi Y, Notoya M, Gohda K, Ueno NT, Ishihara H. Prediction of Dasatinib Sensitivity of Breast Cancer Based on a Novel Tyrosine Kinase-Activity Profiling Assay. 34th Annual San Antonio Breast Cancer Symposium 71(24):549s (#P5-13-02), 12/2011.
50. Cohen EN, Gao H, Lee B-N, Giordano A, Tin S, Anfossi S, Parker CA, Cristofanilli M, Valero V, Alvarez RH, Hortobagyi GN, Woodward WA, Ueno NT, Reuben JM. T-Cell Cytokine Production Related to Progression of Breast Cancer Patients. 34th Annual San Antonio Breast Cancer Symposium 71(24):511s (#OP4-20-03), 12/2011.
51. Debeb BG, Larson R, Xu W, Lacerda L, Reuben JM, Buchholz TA, Ueno NT, Woodward WA. The Effect of Survivin Downregulation on Radiosensitization of Breast Cancer Cell Lines Grown under Adherent and Stem Cell Promoting Culture Conditions. 34th Annual San Antonio Breast Cancer Symposium 71(24):170s (#P1-04-03), 12/2011.
52. Xu W, Debeb B, de Lacerda A, Li L, Larson R, Reuben J, Ueno NT, Woodward W. The Mechanism of Anti-Breast Cancer TICs Effect of Pyrvinium Pamoate Is Through WNT/beta-Catenin Signaling. 34th Annual San Antonio Breast Cancer Symposium 71(24):170s (#P1-04-01), 12/2011.

Book Chapters

1. Ueno, NT, Champlin R. Autologous Transplantation. In: Medical oncology, A Comprehensive Review. PRR, 151-165, 1996.
2. Hung, M, Ueno NT. Targeting HER-2/neu overexpression: Transcriptional repression of HER-2/neu by adenovirus type 5 E1A as a cancer gene therapy. In: Proceeding of the "22nd congress of the international association for breast cancer research.," 85-95, 1998.
3. Ueno NT, Hortobagyi G, Champlin R. Allogeneic peripheral blood progenitor cell transplantation in solid tumors. In: Advance in allogeneic hematopoietic stem cell transplantation. Kluwer Academic Publishers, 133-156, 1999.

5. Ueno NT, Hortobagyi G, Hung, M. Monitoring molecular outcomes of E1A Gene therapy in breast and ovarian cancer. In: Breast Cancer Management: Application of evidence to patient care. Martin Dunitz, 209-219, 2000.
6. Ueno NT, Champlin R. High-dose Chemotherapy as Treatment for High-risk breast Primary and Metastatic Breast Cancer. In: Breast Cancer. M. D. Anderson Cancer Care Series. Springer-Verlag, 2001.
7. [REDACTED]
8. Ueno NT, Andreeff M, Champlin R. High-dose Chemotherapy as Treatment for High-risk Breast Primary and Metastatic Breast Cancer. In: Breast Cancer. New York Inc.: NY, 2006.
9. Ueno NT, Wolf JK, Gershenson DM, Hortobagyi GN, Hung MC. Trials and Tribulations in Developing Clinical Trials of Gene Therapy: E1A for Breast or Ovarian Cancer. Gene Therapy for Cancer. In: Cancer Gene Therapy. Ed(s) Kelly Hunt and Stephan A. Vorburger. Humana Press, 2007.
10. Ueno NT. Emphasis of increase patient satisfaction at The University of Texas M. D. Anderson Cancer Center. In: Medical Student Perspective of Cancer Medicine. Sentan Igakusya: Japan, Chapter 1, pages 16-20; Chapter 2, pages 24-40, 2008.
11. Aikou T, Kitagawa Y, Uenosono Y, Natsugoe S, Bilchik A, Ueno NT. Gastrointestinal Cancer and the Lymphatic System: Patterns of Micrometastasis and Lymphatic Mapping with Clinical Outcome. In: From Local Invasion to Metastatic Cancer. Chapter 4. Ed(s) Stanley P.L. Leong, M.D. Springer, 2008.
12. Ueno NT. Role of Medical Oncologist at M. D. Anderson Cancer Center. In: Medical Student Perspective of Cancer Medicine. Sentan Igakusya: Tokyo, Chapter 1, Pages 16-20, 2008.
13. Ueno NT, Munker R, Atkinson K. Therapeutic decision making in stem cell transplantation for breast cancer. In: THE BMT DATA BOOK 2ND EDITION, 2nd. Ed(s) Munker, H.M. Lazarus, K. Atkinson. Cambridge University Press: USA, 2008.
14. Nakayama K, Ueno NT. Therapy-related infertility in hematological diseases. In: [Rinshō ketsueki] The Japanese Journal of Clinical Hematology. 49, 3, 182-92, 2008.
15. Ueno NT. What I have seen as a doctor. What I noticed after being a patient. In: Facing your daily life (Kurashi-to-mukiau). Astra Zeneca: Japan, 10-15, 2008.
16. Asahi S, Ueno NT. Drug Therapy in Breast Cancer. In: Drug Therapy in Breast Cancer: Japan, 141, 2009.
17. Aikou T, Kitagawa Y, Uenosono Y, Natsugoe S, Bilchik AJ, Ueno NT. Gastrointestinal Cancer and the Lymphatic System: Patterns of Micrometastasis and Lymphatic Mapping with Clinical Outcome. In: From Local Invasion to Metastatic Cancer. Ed(s) SP Leong. Springer, 2009.
18. Costelloe CM, Ueno NT, Lin PP, Yu TK, Hayashi N, Madewell JE. Bone Metastases. In: Oncologic Imaging: A Multidisciplinary Approach. Elsevier Saunders: Philadelphia, 2012.
19. Hayashi N, Onishi T, Ueno NT, Lewis V. Management of Osseous Metastases and Impending Fractures. In: Advanced Therapy of Breast Disease, Third. PMPH-USA: Shelton, 2012.

Books (edited and written)

1. Ueno NT. Ed(s) Hunt K, Robb G, Strom E, Ueno N. Breast Cancer. In: Breast Cancer MD Anderson Cancer Care Series, First. Springer-Verlag: New York, NY, 2001.
2. Ueno NT. Saikouno-iryuu-wo-ukerutameno-kanyaga ku (How to receive ultimate medical care). Koadansha, Alpha-Shinsho, 2006.
3. Ueno NT. Ed(s) Hunt K, Robb G, Strom E, Ueno N. Breast Cancer. In: MD Anderson Cancer Care Series, 2nd. Springer-Verlag: New York, NY, 2007.

4. [REDACTED]
5. [REDACTED]

Letters to the Editor

1. Ueno NT. Commentary for "High-dose chemotherapy with peripheral blood stem cell support for operable locally advanced noninflammatory carcinoma of the breast." Breast diseases: a year book quarterly 11:201-202, 2000.
2. Hortobagyi GN, Ueno NT, Hung MC. E1A is an oncogene and may immortalize normal cells, especially in combination with other oncoproteins - In reply. Journal of Clinical Oncology 19:4183-4184, 2001.

Manuals, Teaching Aids, Other Teaching Publications

1. Ueno NT, Buzdar A, Hortobagyi G. Inflammatory Breast Cancer. 4, 1995.

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Editor, Breast Cancer, M.D. Anderson Monograph, 1999–present

Editor, Oncology Magazine, M. D. Anderson Cancer Center Medical Exchange Program, 2005–present

Editorial Board Member, Journal of Clinical Oncology, American Society of Clinical Oncology, Editorial

Board Member Responsibilities Include: 1. Reviewing at least six manuscripts each year. 2. Writing

editorials and podcast scripts to accompany articles. 3. Providing additional assistance to the Editors

when needed. 4. Responding to any request within 48 hours., 2011–2013

Member of Editorial Review Board

Editor, Journal of Cancer, Ivyspring International Publisher, 2010

Editor Board Member, Journal of Clinical Oncology, American Society of Clinical Oncology, 2011–present

Journal Reviewer

Reviewer, Blood, 1996–present

Reviewer, Cancer Research, 1996–present

Reviewer, Bone Marrow Transplantation, 1997–present

Reviewer, Cancer Letter, 1997–present

Reviewer, Clinical Cancer Research, 1997–present

Reviewer, Journal of Clinical Oncology, 1997–present

Reviewer, Journal of Immunological Methods, 1997–present

Reviewer, Journal of National Cancer Institute, 1997–present

Reviewer, Annals of Oncology, 1999–present

Reviewer, Biology of Blood and Marrow Transplantation, 1999–present

Reviewer, Journal of Biological Chemistry, 1999–present

Reviewer, Oncogene, 1999–present

Reviewer, Breast Cancer Research, 2000–present

Reviewer, International Journal of Hematostudy, 2000–present

Reviewer, Lancet, 2000–present

Reviewer, Cancer Control: Journal of Moffitt Cancer Center, 2002–present

Reviewer, Molecular Cancer Therapeutics, 2005–present

Reviewer, Gynecologic Oncology, 2008–present

Reviewer, Lancet Oncology, 2009–present

Reviewer, Nature Reviews Endocrinology, 2010–present

Other Editorial and Review Activities

Reviewer, San Antonio Breast Cancer Symposium, 2009–present

TEACHING

Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center

Formal Teaching

Courses Taught

Instructor, Human Gene Therapy: Basic Science/Clinical Trial, GSBS, Course Number: GS04 0153,

Course Hours: 2

Spring, 1/2008–8/2010

Training Programs

Lecturer, GSBS Virology and Gene Therapy

8/2000–12/2011

Instructor, GSBS Cancer Biology Program

9/2002–present

Instructor, Cancer Biology, GSBS

Fall, 8/2011–present

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

Committee Chair, GSBS, [REDACTED] 9/2000–5/2004

Research Mentor, GSBS, [REDACTED] 2001–2003

Research Mentor, GSBS, [REDACTED], 2002–2004

Member, GSBS, [REDACTED], 2003–2004

Chair, GSBS, [REDACTED], 9/2005–7/2006

Member, [REDACTED] 12/2009–6/2011

Member, MS Advisory Committee, The University of Texas Graduate School of Biomedical Sciences (GSBS) at Houston, [REDACTED], GSBS, 12/2010–present

Secondary Mentor, [REDACTED] DOD TRIUMPH [REDACTED] 7/2011–present

Member, [REDACTED], The University of Texas Graduate School of Biomedical Sciences Houston, 3/2012–present

Supervisory Committees

Member, [REDACTED], 2001–2003

Member, [REDACTED], 2002–2005

Research Mentor, GSBS, [REDACTED], 10/2007–present

Committee Member, [REDACTED], 4/2010–present

Mentor, Supervisory Committee, [REDACTED] Cancer Biology Ph.D Program, 10/2011–present

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

[REDACTED] 1999

[REDACTED] 1/2000–12/2000

Graduate Students

Research Mentor, Honorable mention in the 10% abstracts submitted to the Clinical/Translational category, Trainee Recognition Day, [REDACTED], 2002

Research Mentor, Research Experience Fellowship in Summer Program for U.S. Graduate Students in Science and Engineering to conduct research in Japan, National Science foundation (NSF) Ministry of Education, Ministry of Culture, Sports, Science and Technology (MEXT), [REDACTED], 6/2002–8/2002

Research Mentor, Travel Award for travel to the American Associated for Cancer Research, The University of Texas Graduate School of Biomedical Sciences [REDACTED], 7/2003

Research Mentor, First Place Winner (Abstract-Oral Presentation) for the Scientific Excellence Award in the Post Candidacy Category, The University of Texas Health Science Center, GSBS [REDACTED], 3/2004

Research Mentor, The University of Texas Graduate School of Biomedical Sciences, [REDACTED] 1/2008–6/2008

Faculty, The University of Texas Graduate School of Biomedical Sciences [REDACTED], 1/2009–4/2011

Mentor, Training Award Finalist -2009 AACR Annual Meeting in Denver, CO, [REDACTED], 4/2009

Faculty, The University of Texas Graduate School of Biomedical Sciences, [REDACTED], 9/2009–12/2009

Faculty, The University of Texas Graduate School of Biomedical Sciences, [REDACTED],
12/2009–2/2010

Faculty, Tutorial Student, The University of Texas Graduate School of Biomedical Sciences, [REDACTED]
[REDACTED] 1/2011–3/2011

Faculty, The University of Texas Graduate School of Biomedical Sciences, [REDACTED]
1/2011–present

Faculty, Tutorial Student, [REDACTED], 9/2011–present

Research Mentor, [REDACTED] 1/2012–3/2012

Postdoctoral Research Fellows

Research Mentor, [REDACTED] 2000–present

Faculty, [REDACTED], 2001–2004

Faculty, [REDACTED], 4/2002–3/2004

Faculty, [REDACTED], 7/2002–12/2004

Faculty, [REDACTED], 12/2002–12/2003

Faculty, [REDACTED] 5/2004–2009

Research Mentor, [REDACTED], 6/2004–8/2006

Faculty, [REDACTED], 8/2004–4/2006

Faculty, [REDACTED], 8/2004–1/2007

Faculty, [REDACTED], 7/2006–present

Faculty, [REDACTED], 6/2007–12/2009

Faculty, [REDACTED], 7/2008–present

Faculty, [REDACTED], 2/2009–12/2010

Faculty, [REDACTED] 12/2009–12/2010

Faculty, [REDACTED] 1/2010–present

Faculty, [REDACTED] 1/2010–present

Faculty, [REDACTED], 2/2010–12/2010

Faculty, [REDACTED], 2011–present

Research Mentor, 2nd place winner for the Abstract Competition of Trainee Research Day 2011, MD
Anderson Training & Alumni Association, [REDACTED] i, 4/2011–5/2011

Research Mentor, One of eight posters chosen for the MD Anderson Trainee & Alumni Poster
Competition of Trainee Research Day 2011, MD Anderson Alumni and Faculty Association, [REDACTED],
4/2011–5/2011

Clinical Residents and Fellows

Faculty, [REDACTED], Medical Oncology, 1998–1999

Faculty, [REDACTED], Stem Cell Transplantation, 1/2001–9/2001

Faculty, [REDACTED], Stem Cell Transplantation, 8/2001–6/2002

Faculty, [REDACTED], Medical Oncology, 8/2001–1/2004

Faculty, [REDACTED], Medical Oncology, 7/2003–6/2006

Research Mentor, [REDACTED], 6/2006–7/2008

Other Supervisory Teaching

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese
TeamOncology Program Participant, 4/2003–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED] Direct Supervision - Japanese
TeamOncology Program Participant, 4/2003–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese
TeamOncology Program Participant, 4/2003–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese
TeamOncology Program Participant, 4/2003–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese
Team Oncology Program Participant, 4/2003–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese
TeamOncology Program Participant, 4/2003–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED] Direct Supervision - Japanese
TeamOncology Program Participant, 4/2003–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED] Direct Supervision - Japanese
TeamOncology Program Participant, 4/2004–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2008–present

Mentor, Japanese TeamOncology Program (JTOP) [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2009–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2009–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED] Direct Supervision - Japanese TeamOncology Program Participant, 4/2009–present

Mentor, Japanese TeamOncology Program (JTOP) [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2009–present

Mentor, Japanese TeamOncology Program (JTOP) [REDACTED] Direct Supervision - Japanese TeamOncology Program Participant, 4/2009–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED] Direct Supervision - Japanese TeamOncology Program Participant, 4/2010–present

Mentor, Japanese TeamOncology Program Participant, [REDACTED] Direct Supervision - Japanese TeamOncology Program Participant, 4/2009–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED] Direct Supervision - Japanese TeamOncology Program Participant, 4/2010–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2010–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED] Direct Supervision - Japanese TeamOncology Program Participant, 4/2010–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED] Direct Supervision - Japanese TeamOncology Program Participant, 4/2010–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2010–present

Faculty, Applicant Interviews, [REDACTED], GSBS Applicant Interviews, 2/2011–present

Faculty, Applicant Interviews, [REDACTED] Applicant Interviews, 3/2011–present

Mentor, Japanese TeamOncology Program (JTOP) [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2011–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2011–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2011–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2011–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2011–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2011–present

Mentor, Japanese TeamOncology Program (JTOP) [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2011–present

Career Development Mentor, Medical Oncology Fellowship, [REDACTED], Mentor, 7/2011–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2012–present

Mentor, Japanese TeamOncology Program (JTOP) [REDACTED] Direct Supervision - Japanese TeamOncology Program Participant, 4/2012–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED] Direct Supervision - Japanese TeamOncology Program Participant, 4/2012–present

Mentor, Japanese TeamOncology Program, [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2012–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED], Direct Supervision - Japanese TeamOncology Program Participant, 4/2012–present

Mentor, Japanese TeamOncology Program (JTOP), [REDACTED] Direct Supervision - Japanese TeamOncology Program Participant, 4/2012–present

Teaching Outside of Current Institution

Formal Teaching

Courses Taught

Lecturer, Career Development in Oncology, Kansai Medical Student Association
7/2008

Lecturer, Case Presentation, Multiple Myeloma, Colon Cancer, Gastric Cancer, Wakayama Medical
College
7/2008

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

Research Mentor, Wakayama Medical College, [REDACTED], 6/2006–present

Mentor, Kanazawa Medical College, [REDACTED], 8/2006–present

Mentor, Okayama University, [REDACTED], 11/2008–present

Graduate Students

Research Mentor, Keio University, [REDACTED], 10/2008–present

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

University of Chicago, [REDACTED], 7/2007–8/2009

Research Mentor, [REDACTED], 6/2009–present

Other Supervisory Teaching

N/A

CONFERENCES AND SYMPOSIA

Organization of Conferences/Symposia (Include chairing session)

The University of Texas MD Anderson Cancer Center and St. Luke International Hospital Joint Open
Forum, M. D. Anderson Cancer Center and St. Luke International Hospital Joint Open Forum, Yokohama,
Japan, Chair, 11/2001

The University of Texas MD Anderson Cancer Center and St. Luke International Hospital Joint Sponsored
Symposium, 39th Japan Society of Clinical Oncology, Hiroshima, Japan, Chair, 11/2001

The University of Texas MD Anderson Cancer Medical Exchange Program, 2nd M. D. Anderson Cancer
Medical Exchange Program, Kyoto, Japan, Chair, 9/2002

iwNST, 4th International Workshop on Non-myeloablative Stem Cell Transplantation, Bermuda, Chair,
2/2003

The University of Texas MD Anderson Cancer Medical Exchange Program, M. D. Anderson Cancer
Medical Exchange Program, Kazusa, Japan, Chair, 9/2003

The University of Texas MD Anderson Cancer Medical Exchange Program, 3rd M. D. Anderson Cancer
Medical Exchange Program, Tokyo, Japan, Chair, 9/2004

Japanese Breast Cancer Society, NCCN guideline in Breast Cancer, Okayama, Japan, Chair, 6/2005

The University of Texas MD Anderson Cancer Medical Exchange Program, 4th M. D. Anderson Cancer
Medical Exchange Program, Osaka, Japan, Chair, 9/2005

The European Group for Blood & Marrow Transplantation, 2nd International Meeting of Allogeneic
Transplantation for Solid Tumor, Milan, Italy, Chair, 10/2005

The University of Texas MD Anderson Cancer Medical Exchange Program, 5th M. D. Anderson Cancer
Medical Exchange Program, Kyoto, Japan, Chair, 10/2006

St. Luke Life Science Foundation, 1st Japan TeamOncology Workshop, Makuhari, Japan, Chair, 11/2007
The European Group for Blood & Marrow Transplantation, 3rd International Meeting of Allogeneic Transplantation for Solid Tumor, Siena, Italy, Chair, 3/2008
Academy of Cancer Experts (ACE) Program, 1st Multidisciplinary Clinical and Translational Research Workshop, Tokyo, Japan, Chair, 8/2008
2nd Japan TeamOncology Workshop, St. Luke Life Science Foundation, Sapporo, Japan, Chair, 11/2008
Japan Patient Advocacy Liaison, Japan Patient Advocacy Liaison Workshop "Patient Empowerment," Tokyo, Japan, Moderator, 12/2008
Academy of Cancer Experts (ACE) Program, 2nd Multidisciplinary Clinical and Translational Research Workshop, Tokyo, Japan, Chair, 2/2009
Academy of Cancer Experts (ACE) Program, 3rd Multidisciplinary Clinical and Translational Research Workshop, Academy of Cancer Experts (ACE) Program @ Keio University, Tokyo, Japan, Chair, 7/2009
Japan - US Clinical Trials Exploring Collaboration, CTEP, US Embassy, Tokyo, Japan, Moderator, 7/2009
Career Development in Oncology, Pfizer, St. Luke Life Science Foundation, Tokyo, Japan, Chair, 10/2009
3rd Japan TeamOncology Workshop, St. Luke Life Science Foundation, Tokyo, Japan, Chair, 11/2009
32nd Annual CTIC-AACR San Antonio Breast Cancer Symposium, CTIC-AACR, San Antonio, TX, Abstract Reviewer Committee, 12/2009
4th Japan TeamOncology Workshop, Oncology Education Project, Fukuoka, Japan, Chair, 11/2010
Autologous and Allogeneic Cellular Therapy in Solid Tumors, Venice, Italy, Chair, 3/2011
5th Japan TeamOncology Workshop, Oncology Education Project, Tokyo, Japan, Founder, 11/2011
J-HOPE, Oncology Education Project, Obihiro, Japan, Chair, 11/2011

Presentations at National or International Conferences

Invited

Chemosensitization of HER-2/neu-overexpressed breast cancer cells to paclitaxel (Taxol) by adenovirus 5 E1A, Annual Meeting of American Association for Cancer Research, Poster discussion, Washington, DC, 4/1996

Chemosensitization of HER-2/neu-overexpressed breast cancer cells to paclitaxel (Taxol) by adenovirus 5 E1A, Cold Spring Harbor Laboratory, Gene Therapy meeting, Poster presentation, Cold Spring Harbor, NY, 9/1996

Chemosensitization of HER-2/neu-overexpressed breast and ovarian cancer cells to paclitaxel (Taxol) by adenovirus 5 E1A, American Society of Blood and Marrow Transplantation. Novel approach in blood and marrow transplantation, Oral Presentation, San Diego, CA, 10/1996

Allogeneic blood stem cell transplantation for induction of graft versus tumor effect in patients with metastatic breast cancer, Annual Meeting of American Society of Clinical Oncology, Oral Presentation, Denver, CO, 5/1997

Allogeneic transplantation for metastatic breast cancer. Oral Presentation, IBMTR, Oral Presentation, Keystone, CO, 1998

Phase I E1A gene therapy in patients with advanced breast and ovarian cancers, Annual Meeting of American Association for Cancer Research, Oral Presentation, New Orleans, LA, 3/1998

Phase I E1A gene therapy in patients with advanced breast and ovarian cancers, Annual Meeting of American Society of Clinical Oncology, Poster presentation, Los Angeles, CA, 5/1998

Phases I E1A gene therapy in patients with advanced breast and ovarian cancers, 1st Annual Meeting of American Society of Gene Therapy, Oral Presentation, Seattle, WA, 5/1998

Allogeneic transplantation in metastatic breast cancer, 25th Annual European Group for Blood and Marrow Transplantation and 15th Annual Nurses Group Meeting, Oral Presentation, Hamburg, Germany, 3/1999

E1A-mediated paclitaxel (Taxol) sensitization in HER-2/neu-overexpressing ovarian cancer through apoptosis involving caspase-3 pathway, Annual meeting of American Association for Cancer Research, Mini-symposium, Philadelphia, PA, 4/1999

Combined E1A gene therapy and Taxol in HER-2/neu-overexpressing ovarian cancer, 2nd Annual meeting of American Society of Gene Therapy, Poster presentation, Washington, DC, 6/1999

Allogeneic transplantation in breast cancer, Strategie Innovative Nel Trattamento Del Carcinoma Mammario, Oral Presentation, Castellanza, Italy, 1/2000

High-dose chemotherapy in breast cancer. Herceptin and E1A gene therapy in HER-2/neu-overexpressing breast cancer, Istanbul, Turkey, 2/2000

Experience of allogeneic transplantation in metastatic breast cancer, 26th Annual European Group for Blood and Marrow Transplantation and 16th Annual Nurses Group Meeting, Oral Presentation, Innsbruck, Austria, 3/2000

Transplantation in Hematology and Oncology II, Satellite symposium II: autologous vs. allogeneic transplantation: Current concepts and future trends, Oral Presentation, Münster, Germany, 4/2000

High-dose chemotherapy (HDCT) for primary breast cancer refractory to neoadjuvant chemotherapy (NAC), International Conference on High-dose Chemotherapy in breast and ovarian cancer, Oral Presentation, Florence, Italy, 9/2000

Evolving role of BMT for Breast Cancer, Blood & Marrow Transplantation: State of the Art in Manage Care Conference, Oral Presentation, 10/2000

Non-myeloablative transplantation, Japanese Society of Clinical Hematology: Luncheon Seminar, Oral Presentation, Kurashiki, Japan, 11/2000

Non-myeloablative transplantation, NST forum, Oral Presentation, Kurashiki, Japan, 11/2000

High-dose chemotherapy (HDCT) for primary breast cancer refractory to neoadjuvant chemotherapy (NAC), Annual meeting of the American Society of Clinical Oncology, Poster presentation, San Francisco, CA, 5/2001

E1A gene therapy: Downregulation of HER-2/neu and induction of apoptosis, 9th Annual Meeting of the Japanese Breast Cancer Society, Maebashi, Japan, 6/2001

Hiroshima Consensus Meeting for Breast Cancer, 39th Japan Society of Clinical Oncology, Hiroshima, Japan, 11/2001

Can Hematopoietic Stem Cell Transplantation Cure Breast Cancer, Fondazione Matarelli Educational Symposium - Hematopoietic Stem Cell Therapy: The Basic Questions, Milan, Italy, 2/2002

Allogeneic Transplantation with Reduced Intensity Conditioning Regimes., Kozukata Hematology Symposium, Oral Presentation, Morioka, Japan, 3/2002

Complete donor chimerism by fludarabine/melphalan in mini-allogeneic Peripheral Blood Progenitor Cell (PBPC) Transplantation for Metastatic Renal Cell Carcinoma (RCC) and Metastatic Breast Cancer (BC), Annual meeting of American Society of Clinical Oncology, Oral presentation, Orlando, FL, 5/2002

Complete donor chimerism by fludarabine/melphalan in mini-allogeneic transplantation for metastatic breast carcinoma, Milan, Italy, 6/2002

Role of Bone Marrow Transplantation in RCC, New Direction in Renal Cell Carcinoma, Kidney Cancer Society, Oral Presentation, Houston, TX, 8/2002

E1A gene therapy in Solid Tumor, Osaka, Japan, 2/2003

Preparation of preprinted order at M. D. Anderson Cancer Center, Tokyo, Japan, 2/2003

The latest update for Allogeneic Transplantation in Solid Tumor, 8th Tokai Hematopoietic Stem Cell Transplantation Symposium, Oral Presentation, Nagoya, Japan, 2/2003

International bone marrow transplant registry/The European Group for Blood and Marrow Transplantation review of allogeneic hematopoietic stem-cell transplantation in metastatic breast cancer, Annual meeting of American Society of Clinical Oncology, Oral presentation, Chicago, IL, 6/2003

Low prevalence of premature ovarian failure (POF) in women who received reduced-intensity conditioning (RIC) regimens for hematopoietic stem-cell transplantation (HST), Annual meeting of American Society of Clinical Oncology, Poster Discussion, Chicago, IL, 6/2003

Multidisciplinary approach in breast cancer management: role of pharmacist, Oncology PharmD Tokyo Forum, Tokyo, Japan, 8/2003

Recent update of Cancer Medicine in USA, Kobe, Japan, 8/2003

The latest update for Allogeneic Transplantation in Solid Tumor, 41st Annual Meeting of Japanese Society of Clinical Oncology, Oral Presentation, Sapporo, Japan, 10/2003

Update of Cancer Gene Therapy, 41st Annual Meeting of Japanese Society of Clinical Oncology, Oral Presentation, Sapporo, Japan, 10/2003

Ethical Issues in Transplantation: Panel Discussion, American Society for Blood and Marrow Transplantation, Orlando, FL, 2/2004

Hematopoietic stem cell transplantation for breast cancer: Resolved Issue, American Society for Blood and Marrow Transplantation, Oral Presentation, Orlando, FL, 2/2004

Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Mini-symposia, Annual meeting of the American Association for Cancer Research, Orlando, FL, 3/2004

Outpatient chemotherapy-Multidisciplinary Approach, 7th Breast Cancer up-to-date meeting, Yokohama, Japan, 3/2004

US Medical Oncology Fellowship, 2nd Annual Meeting of Japanese Society of Medical Oncology, Tokyo, Japan, 3/2004

Novel prognostic profiling in breast cancer, 1st Tokyo Metropolitan PharmD mtg, Tokyo, Japan, 7/2004

Novel prognostic profiling in breast cancer, Annual Meeting of Breast Cancer Update, Oral Presentation, Wakayama, Japan, 7/2004

Japanese Urological Association, 54th Annual Meeting of Central Section of Japanese Urological Association, Oral Presentation, Sennan, Japan, 11/2004

Depends on Cyclin-Dependent Kinase 2 Activity, Annual meeting of the American Association for Cancer Research. Mini-symposia, Anaheim, CA, 4/2005

Role of Hematopoietic Stem Cell Transplantation in Non-myeloablative allogeneic transplantation, Oral Presentation, Bern, Switzerland, 5/2005

Outpatient chemotherapy for breast cancer, 6th Breast Cancer Conference Up to date, Oral Presentation, Karuizawa, Japan, 7/22/2005

Bone Metastasis: Strategy and Tactics, Japanese Society of Clinical Oncology, Oral Presentation, Nagoya, Japan, 10/2005

Exploring the future of Oncology Specialists, Japanese Society of Clinical Oncology, Oral Presentation, Nagoya, Japan, 10/2005

Recent advances in allogeneic transplantataion for breast cancer, 2nd International Meeting of Allogeneic Transplantation for Solid Tumor, Oral Presentation, Stretsa, Italy, 10/2005

Development of Clinical Pathway, Japanese Society of Clinical Pathway, Oral Presentation, Niigata, Japan, 12/2005

Education difference for hematologist between US and Japan, 28th Annual meeting of Japanese Society of Hematopoietic Cell Transplantation, Oral Presentation, Tokyo, Japan, 2/2006

Role of Allogeneic Transplantation in Solid Tumor, 28th Annual meeting of Japanese Society of Hematopoietic Cell Transplantation, Oral Presentation, Tokyo, Japan, 2/2006

Multidisciplinary Cancer Care, Japanese Society of Clinical Oncology, Oral Presentation, Tokyo, Japan, 10/2006

Role of Circulating Tumor Cells in Breast Cancer, Japanese Society of Clinical Oncology, Oral Presentation, Tokyo, Japan, 10/2006

Role of Family in Cancer Care, 3rd Wellness Community, Oral Presentation, Tokyo, Japan, 10/2006

Role of pharmacist in multidisciplinary cancer treatment, 16th Annual Meeting of the Society of Pharmaceutical Careas and Science, Oral Presentation, Kanazawa, Japan, 10/2006

Use of Breast Cancer Treatment Guideline, 14th Annual Meeting of the Japanese Breast Cancer Society, Oral Presentation, Kanazawa, Japan, 10/2006

Multidisciplinary Cancer Treatment, 21st Annual Meeting of Japanese Society of Cancer Nursing, Oral Presentation, Tokyo, Japan, 2/2007

Role of Circulating Tumor Cells in Bone Marrow Micrometastasis in Breast Cancer, 2nd International Symposium of Cancer Metastasis and Lymphovascular Medicine, San Francisco, CA, 5/2007

Dose Intensification for Adjuvant Therapy for Patients with Triple Negative Breast Cancer?, 15th Annual Meeting of Japanese Society of Breast Cancer, Yokohama, Japan, 6/2007

Phase III randomized study of Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation vs Adjuvant Dose-Dense Chemotherapy for Patients with High-Risk Primary Breast Cancer, JSCT, Yokohama, Japan, 6/2007

Promoting Multidisciplinary Breast Cancer Care and Researach, 15th Annual Meeting of Japanese Society of Breast Cancer, Oral Presentation, Yokohama, Japan, 6/2007

Prospective study of spindle assembly checkpoint a (SAC) to predict breast tumor response to taxanes, Annual meeting of American Society of Clinical Oncology. Poster Presentation, Chicago, IL, 6/2007

Prospective study of spindle assembly checkpoint (SAC) to predict breast tumore response to taxanes, 2007 Breast Cancer Symposium, Poster Presentation, San Francisco, CA, 9/2007

TeamOncology ABC: Current Status and Future View of Multidisciplinary Care, 17th Annual Meeting of the Society of Pharmaceutical Cares and Science, Oral Presentation, Maebashi, Japan, 9/2007

Creation of TeamOncology ABC: Current Status and Future View of Multidisciplinary Care, 45th Annual Meeting of the Japanese Society of Clinical Oncology, Kyoto, Japan, 10/2007

Systemic Treatment Options for Bone Metastasis, 8th Annual Oncology Update Advance and Controversies, Park City, UT, 1/2008

Can allogeneic transplantation cure metastatic breast cancer, 3rd International Meeting of Allogeneic Transplantation for Solid Tumor, Italy, 3/2008
Development of Biomarker for Non-novel Drug, Kobe University & 6th Hyogo Cancer Society, Kobe, Japan, 7/2008
Development of Biomarkers and Clinical Trials Based on Laboratory Findings, Japan Society of Clinical Oncology, Nagoya, Japan, 10/31/2008
EBM: Examiner, Creator, and Follower, Japan Society of Clinical Oncology, Nagoya, 11/1/2008
Zhang D, LaFortune TA, Hortobagyi GN, Cristofanilli M, Lucci A, Singh B, Hung, MC, Ueno NT. Reversal of mesenchymal to epithelial phenotype by EGFR tyrosine kinase inhibitor in inflammatory breast cancer, First International Inflammatory Breast Cancer Conference, Houston, TX, 12/5/2008
Transmembrane growth factor receptor pathways in IBC, First International Inflammatory Breast Cancer Conference, Houston, TX, 12/5/2008
Paradigm Shift in Oncologic Drug/Biomarker Development, Japanese Association for Molecular Targeted Therapy of Cancer, Tokushima, Japan, 6/25/2009
Development of Biomarkers in Breast Cancer, 6th Annual Meeting of Guangdong Breast Cancer Meeting, Guangzhou, China, 6/27/2009
Ueno NT. Practical use of guidelines for management of breast cancer, ASCO/JSMO, The 8th Annual Meeting of Japanese Society of Medical Oncology, Tokyo, Japan, 3/18/2010
Ueno NT. Multi-disciplinary Care with Targeted Therapies, The 8th Asia Pacific Oncology Summit, Tokyo, Japan, 3/21/2010
Multidisciplinary Cancer Care at MD Anderson Cancer Center, 9th International Conference of Asian Clinical Oncology Society, Gifu, Japan, 8/26/2010
Multidisciplinary Care at MD Anderson Cancer Center: Past, Present, and Future and the Role of Pharmacist, The Japanese Society of Hospital Pharmacists, Tokyo, Japan, 8/28/2010
Molecular Changes and Targeted Therapy in Inflammatory Breast cancer, 4th Seoul Breast Cancer Symposium, Seoul, Korea, Republic of, 8/29/2010
Successful team building in multidisciplinary cancer care, Ryukyu University, Naha, Japan, 9/2/2010
Synergistic Effect of Conventional Therapy with Targeted Therapy, 2010 Taipei International Breast Cancer Symposium, Taipei, Taiwan, 9/5/2010
Ueno NT. Targeting the Epithelial-mesenchymal Transition to Reduce Metastasis of Inflammatory Breast Cancer, Breast Cancer Symposium, ASCO, Washington DC, 10/1/2010
Ueno NT. Role of Cancer Stem Cells in Breast Cancer. Is this a real target?, 1st Regional Conference on Cancer Molecular Targeted Therapy, Minister of Health, Kuwait, Kuwait City, Kuwait, 2/19/2011
Regulation of Metastasis by EGFR targeted therapy, 4th Autologous and Allogeneic Cellular Therapy in Solid Tumors meeting, 4th Autologous and Allogeneic Cellular Therapy in Solid Tumors meeting, Venice, Italy, 3/21/2011
Breast Cancer Meta-analysis of High Dose Chemotherapy, 4th Autologous and Allogeneic Cellular Therapy in Solid Tumors meeting, 4th Autologous and Allogeneic Cellular Therapy in Solid Tumors meeting, Venice, Italy, 4/1/2011
Ueno NT. ABC of Multidisciplinary Approach in Cancer, Hokkaido Hospital Congress, Hokkaido Hospital Congress, Sapporo, Japan, 7/9/2011
Ueno, NT. Advanced and recurrence breast cancer treatment for hormonal receptor positive breast cancer, AstraZeneca, Japanese Breast Cancer Society, Sendai, Japan, 9/2/2011
Clinical Trials in USA, JSCO, Nagoya, Japan, 10/30/2011
Inflammatory Breast Cancer: An update and progress, Bristol-Myers, Japanese Breast Cancer Society, Kumamoto, Japan, 6/29/2012

Other, Including Scientific Exhibitions
Systemic E1A gene therapy breast and head/neck cancer, Annual meeting of the American Association for Cancer Research. Poster presentation, New Orleans, LA, 3/2001
Bench to Clinic. What are the issues that we are facing at MDA?, Japanese Cancer Association, Nagoya, Japan, 10/30/2008
Suppression of Mesenchymal Phenotype in Inflammatory Breast Cancer by EGFR Tyrosine Kinase Inhibitor Erlotinib: A Novel Approach to Suppressing Metastasis, 2008 San Antonio Breast Cancer Symposium - Poster Presentation, San Antonio, TX, 12/10/2008
Team Oncology, Japan TeamOncology Program, Osaka, Japan, 2/15/2009
Creating the best Team for Cancer Care, Kochi University, Kochi, Japan, 2/17/2009

How to receive the best medical care?, Itsuki-kai, Kochi, Japan, 2/17/2009
ACE activity in Japan, Development of CTEP investigator initiated trials, CTEP, US Embassy, Tokyo, Japan, 7/3/2009
Current Treatment Practice for metastatic breast cancer, Japanese Breast Cancer Society, Tokyo, Japan, 7/3/2009
Practical use of CTCs in Metastatic Breast Cancer, Japanese Breast Cancer Society, Tokyo, Japan, 7/4/2009
Advanced in Cancer Treatment. What you need to know?, The 47th Annual Meeting of Japanese Society of Clinical Oncology, The 47th Annual Meeting of Japanese Society of Clinical Oncology, Morioka, Japan, 7/18/2009
Mego M, De Giorgi U, Dawood S, Andreopoulou E, Valero V, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Kinetics of circulating tumor cells in metastatic breast cancer patients, 7th International Symposium on Minimal Residual Cancer, Greece, Greece, 9/16/2009
Creating Research-driven TeamOncology, The 47th Annual Meeting of Japanese Society of Clinical Oncology, Yokohama, Japan, 10/22/2009
Achieving a consensus in Cancer Multi-disciplinary Care, The 47th Annual Meeting of Japanese Society of Clinical Oncology, Yokohama, Japan, 10/23/2009
What can we do to bring Health Care Reform in Cancer?, The 47th Annual Meeting of Japanese Society of Clinical Oncology, Yokohama, Japan, 10/23/2009
What do you need to know when you are diagnosed cancer?, The 47th Annual Meeting of Japanese Society of Clinical Oncology, The 47th Annual Meeting of Japanese Society of Clinical Oncology, Yokohama, Japan, 10/24/2009
Yamauchi H, Nakamura S, Zhang D, Hortobagyi GN, Cristofanilli M, Ueno NT. Potential of molecular targeted therapy for inflammatory breast cancer, Japanese Surgical Association, 71st Annual Congress of Japanese Surgical Association, Tokyo, Japan, 11/19/2009
LaFortune TA, Ordentlich P, Zhang D, Hortobagyi GN, Cristofanilli M, Ueno NT. Synergistic Effect of Lapatinib and the Class 1 HDAC Inhibitor SNDX-275 in Breast Cancer, 2009 San Antonio Breast Cancer Symposium-Poster Presentation, San Antonio, TX, 12/10/2009
Imamura CK, Takebe N, Nakamura S, Saya H, Ueno NT. Support system of MCI/CTEP for cancer clinical trials in the U.S>, Japan Society of Clinical Trials and Research 1st Annual Meeting, Japan Society of Clinical Trials and Research, Tokyo, Japan, 2/9/2010
Role of EGFR Pathway Regulation in EMT of Inflammatory Breast Cancer, AACR, Arlington, VA, 2/28/2010
Oishi T, Bartholomeusz C, Nonaka M, Naniwa J, Uegaki K, Sato S, Shimada M, Itamochi H, Harada T, Kigawa J, Ueno NT. ERK-targeted therapy suppresses tumorigenicity in ovarian clear cell carcinoma, 69th annual meeting of Japanese Cancer Association, Japanese Cancer Association, Osaka, Japan, 9/22/2010
Inflammatory Breast Cancer Registry Consortium, 2nd International Inflammatory Breast Cancer Conference, Marseilla, Italy, 10/7/2010
Ueno NT. Molecular Changes and Targeted Therapy in Inflammatory Breast Cancer, 1st Regional Conference on Cancer Molecular Targeted Therapy, Minister of Health, Kuwait, Kuwait City, Kuwait, 2/19/2011
Simon, J, Franki, R, Crump, D, Rogers, J, Phillips, S, Ellebracht, S, Ueno, NT, Wendt III, R. Preclinical evaluation of Sm-153-DOTMP as a therapeutic bone-seeking radiopharmaceutical, 2011 Annual Meeting of the Society of Nuclear Medicine, San Antonio, TX, 6/4/2011
Novel Approaches to Develop Targeted Therapies in Advanced Breast Cancer, Japanese Breast Cancer Society, Japanese Breast Cancer Society, Sendai, Japan, 9/2/2011
Recent advances of genome researches and related clinical trials in breast cancer, International Symposium on Emerging Femal Cancers in Asia, Taipei, Taiwan, 6/30/2012
Seminar Invitations from Other Institutions
E1A gene therapy against HER-2/neu-overexpressing cancer. Bench research to clinical trial, Institute for Drug Development, San Antonio, TX, 11/1997
E1A gene therapy against HER-2/neu-overexpressing cancer. Bench research to clinical trial, Mexico City, Mexico, 11/1/1997
Allogeneic transplantation in breast cancer. Allogeneic transplantation: What every oncologist needs to know, Ireland Cancer Center at Case Western Reserve Univ, Cleveland, OH, 6/1998

Development of gene therapy in breast and ovarian cancer, Encino Tarzana Regional Medical Center, Tarzana, CA, 11/1998

Development of E1A gene therapy in breast and ovarian cancer, Wakayama Medical College, Wakayama City, Japan, 12/1998

High-dose chemotherapy and autologous transplantation combined with Herceptin and Taxol, Herceptin investigators meeting, San Francisco, CA, 8/1999

Herceptin and E1A Gene Therapy in HER-2/Neu-Overexpressing Breast Cancer, Breast Cancer Symposium, Oral Presentation, Breast Cancer Symposium, Istanbul, Turkey, 2/2000

High-Dose Chemotherapy in Breast Cancer, Breast Cancer Symposium, Oral Presentation, Breast Cancer Symposium, Istanbul, Turkey, 2/2000

Current update in non-myeloablative Allogeneic Transplantation, Center for Adult Disease, Osaka, Japan, 7/2000

Development of E1A gene therapy in breast and ovarian cancer, Wakayama Medical College, Wakayama City, Japan, 7/2000

How to Become a Medical Oncologist, St. Luke International Hospital, Tokyo, Japan, 7/2000

Herceptin Targeted Biologic Therapy for Patients with HER-2/neu-overexpressing Breast Cancer: Fact and Future Direction, Tokyo, Japan, 7/8/2000

Herceptin Targeted Biologic Therapy for Patients with HER-2/neu-overexpressing Breast Cancer: Fact and Future Direction, Fukuoka, Japan, 7/11/2000

Herceptin Targeted Biologic Therapy for Patients with HER-2/neu-overexpressing Breast Cancer: Fact and Future Direction, Osaka, Japan, 7/12/2000

Current update in Allogeneic Transplantation in solid tumor, Tokyo, Japan, 7/14/2000

Development of E1A gene therapy in breast and ovarian cancer, Karmonas Cancer Institute, Detroit, MI, 10/2000

Non-myeloablative transplantation, Japan Medical College, Tokyo, Japan, 11/2000

Future Direction of Non-myeloablative Allogeneic Transplantation, GRAN Scientific Symposia, Yokohama, Japan, 7/2001

Future Direction of Non-myeloablative Allogeneic Transplantation, GRAN Scientific Symposia, Nagoya, Japan, 7/2001

Future Direction of Non-myeloablative Allogeneic Transplantation, GRAN Scientific Symposia, Wakayama, Japan, 7/2001

Future Direction of Non-myeloablative Allogeneic Transplantation, GRAN Scientific Symposia, Morioka, Japan, 7/2001

Role of Multidisciplinary Care in success of Non-myeloablative Allogeneic Transplantation, GRAN Scientific Symposia, Chiba, Japan, 7/2001

Role of Multidisciplinary Care in success of Non-myeloablative Allogeneic Transplantation, GRAN Scientific Symposia, Sakai, Japan, 7/2001

Non-myeloablative Stem Cell Transplantation (NST) in Metastatic Solid tumor (MDACC/EBMT Breast Cancer Experience, Breast Cancer Experience, Breast Cancer Experience, Captiva Island, FL, 1/2002

Transplantation in Breast Cancer, Breast Cancer Experience, Captiva Island, FL, 1/2002

Gene Therapy for Gynecologic Cancers, Bristol-Myers Squibb International Oncology Visiti, Houston, TX, 3/2002

Making EBM & Practicing EBM in Breast Cancer --- Ideality and Reality, ASCO2002/Orland Pharmacia Japan Program, Orlando, FL, 5/2002

Future Direction and Issues-related to targeted therapy: E1A gene therapy in solid tumor, Kumamoto University, Kumamoto, Japan, 7/2002

Latest update of allogeneic transplantation in solid tumor, National Defense Medical College, Ommaya, Japan, 7/2002

The latest update in NST: hematological malignancy and solid tumor, Okayama University, Okayama, Japan, 7/2002

The latest update in NST: hematological malignancy and solid tumor, Nagasaki University, Nagasaki, Japan, 7/2002

The latest update of allogeneic transplantation in solid tumor, Hiroshima University, Hiroshima, Japan, 7/2002

The latest update of allogeneic transplantation in solid tumor, Kyushu University, Fukuoka, Japan, 7/2002

The latest update of allogeneic transplantation in solid tumor, Imamura Hospital, Kagoshima, Japan, 7/2002

What is a standard therapy in breast cancer? Experience of clinical trial development at M. D. Anderson Cancer Center, Tokyo, Japan, 7/26/2002

High Risk Breast Cancer Patients for Recurrence and their prevention, Tokyo, Japan, 7/27/2002

Future direction of non-myeloablative allogeneic transplantation in solid tumor, Kanazawa University, Kanazawa, Japan, 7/2003

Role of pharmacist in multidisciplinary care, Kobe Pharmacy Association, Kobe, Japan, 7/2003

Role of G-CSF in breast cancer management, Kirin Corp, Tokyo, Japan, 8/2003

Role of pharmacist in multidisciplinary care, Tokyo Metropolitan Pharmacy Association, Kobe, Japan, 8/2003

Mindset, Multidisciplinary Care, Tokyo Cancer Research Hospital, Tokyo, Japan, 6/2004

Advancement in NST, Tokyo, Japan, 6/26/2004

Advancement in NST, Kyoto Prefectural Medical College, Kyoto, Japan, 7/2004

Mindset, Multidisciplinary Care, Shizoka Cancer Center, Mishima, Japan, 7/2004

Development of E1A gene therapy, Osaka Adult Disease Center, Osaka, Japan, 11/2004

Development of E1A gene therapy, Tottori University, Yonago, Japan, 11/2004

Role of Hematopoietic Stem Cell Transplantation in Breast Cancer, Mofitt Cancer Center, Tampa, FL, 11/2004

Development of novel biomarker in breast cancer, Kumamoto University, Kumamoto, Japan, 7/2005

Multidisciplinary Care in Cancer, Juntendo University, 7/2005

Development of patient-oriented multidisciplinary care in cancer, 21st Century COE Program: The 4th International Relay Symposium, St. Luke College of Nursing, 10/2005

Multidisciplinary Care in Cancer, Wakayama Oncology Symposium, Wakayama Medical College, Wakayama, Japan, 12/2005

Hig-Dose Chemotherapy in Breast Cancer, Is it Obsolete?, West German Study Group, Oral Presentation, West German Study Group, Duserdorff, Germany, 5/2006

Multidisciplinary Care in Cancer, Hyogo Medical Center for Adults, Hyogo, Japan, 6/2006

Development of Novel Prognostic Markers in Breast Cancer, Iwate Medical College, Iwate Medical College, Morioka, Japan, 7/2006

Multidisciplinary Cancer Treatment, Kanazawa Medical College, Kanazawa Medical College, Kanazawa, Japan, 9/2006

Is There Really a Role of Taxene?, 7th Annual Oncology Update: Advances and Controversies. M. D. Anderson Cancer Center, Oral Presentation, 7th Annual Oncology, Steamboat, CO, 1/2007

Role of Biomarker in Breast Cancer, International Conference of Medical Education in Oncology, Medical Education in Oncology, Izumo, Shimane, Japan, 1/2007

Translational Research in Breast Cancer, Keio University, Tokyo, Japan, 4/2007

Opportunities and Challenges in Advancing Breast Cancer Treatment, Bristol Myers 10th Anniversary of Paclitaxel, Bristol Myers, Tokyo, Japan, 9/2007

Role of minimal residual disease in breast cancer, Kirin Pharmaceutical Research Group for Discovery, Takasaki, Japan, 9/2007

Advances in Treatment of Bone Metastasis, 2nd Annual Metastatic Breast Cancer Network Conference, Metastatic Brease Cancer Network, Houston, TX, 11/2007

Role of Medical Oncologist in US, International Conference of Medical Education in Oncology, International Conference of Medical Education in Oncology, Tohoku, Sendai, Miyagi, Japan, 2/2008

Development of Biomarker Based on Non-Novel Drugs, Tokai University, Tokai University, Yokohama, Japan, 7/2008

Multidisciplinary Care at M. D. Anderson Cancer Center, Mission and Vision, St. Luke Life Science Foundation, Japan, 7/2008

Patient Advocacy, Japan Pharmaceutical Manufacturers Association, JPMA, Tokyo, Japan, 7/2008

What is Multidisciplinary Cancer Care?, Tokyo University Hospital, Tokyo University Hospital, Tokyo, Japan, 7/2008

What is Multidisciplinary Cancer Care?, Hokuto Hospital, Hokuto Hospital, Obihiro, Japan, 7/2008

What is Multidisciplinary Cancer Care?, Kanagawa Cancer Center, Kanagawa Cancer Center, Yokohama, Japan, 7/2008

How to receive the best medical care?, 3rd New York Breast Cancer Seminar, NY Breast Cancer Network, NY, NY, 10/26/2008
Present Status of Medical School in US, Tokyo Metropolitan Government, Tokyo, Japan, 10/30/2008
The issues in cancer care in Japan, Media Forum (Chugai-Roche), Tokyo, Japan, 10/31/2008
Success of Multidisciplinary Care in Oncology, Shikoku Cancer Center, Matsuyama, Japan, 11/18/2008
Career Development in Nursing, Kochi University, Kochi, Japan, 2/17/2009
Creating the best Team for Cancer Care, National Cancer Center Hospital (NCI Japan), Tokyo, Japan, 2/18/2009
How to receive the best medical care?, JPMA, Tokyo, Japan, 2/18/2009
Development of Biomarkers in Breast Cancer, Kyoto University, Kyoto, Japan, 3/21/2009
Development of Biomarkers in Breast Cancer. Difficulties and Excitement, University of Calgary, Graduate School of Biomedical Science, Calgary, Canada, 5/7/2009
Role of Allogeneic Transplantation in Solid Tumor, University of Texas, Houston, Houston, TX, 5/28/2009
Creating an Effective Oncology Team, Hokuto Hospital, Obihiro, Japan, 7/14/2009
Multidisciplinary Care in Oncology, Tokyo Medical University, Tokyo, Japan, 7/15/2009
Multidisciplinary Care in Oncology, Aomori Health University, Aomori, Japan, 7/17/2009
What do you do when you are diagnosed cancer?, Astrazeneca and Evidence, Inc., Astrazeneca and Evidence, Inc., Tokyo, Japan, 10/17/2009
Special Remark for Creating the Sarcoma Center at NCI Japan, National Cancer Center Hospital, Tokyo, Japan, 10/19/2009
The Importance of Government Support for an Academic/Public Clinical Trial Network to Complement Industry-Supported Trials, US Government, State Department, US Embassy, Tokyo, Tokyo, Japan, 10/20/2009
The Importance of Patient Advocacy Movement, US Government, State Department, US Embassy, Tokyo, Tokyo, Japan, 10/20/2009
Successful team building in multidisciplinary care, Okayama University, Surgery, Okayama, Japan, 11/9/2009
Successful team building in multidisciplinary care, Himeji Red Cross Hospital, Himeji, Japan, 11/10/2009
Multi-disciplinary Cancer Care, Democratic Party, Japan, Tokyo, Japan, 3/18/2010
Patient Empowerment Process: How to receive the best medical care !, Life Time Empowerment Program, Tokyo, Japan, 3/20/2010
Triple Negative Breast Cancer = TNBC, Hokuto Hospital, Obihiro, Japan, 6/12/2010
Successful team building for cancer care by mid-level practitioner!, Tokia University, Japan, 6/17/2010
Cancer Survivor Ship Talk, Cancer Net Japan, Tokyo, Japan, 6/26/2010
Role of Alternative Medicine, Cancer Net Japan, Tokyo, Japan, 6/27/2010
Success of Multidisciplinary Care in Oncology, Aomori University of Health and Welfare, Aomori, Japan, 6/30/2010
Molecular Changes and Targeted Therapy in Inflammatory Breast cancer, Case Western Comprehensive Cancer Center, Cleveland, OH, 7/30/2010
Successful team building for multi-disciplinary cancer care (TeamOncology), Saitama Medical College, Medical Oncology, Oomiya, Japan, 8/31/2010
Targeted Therapy in Breast Cancer, Kumamoto University, Kumamoto, Japan, 10/31/2011
Team Medicine: Shared Vision and Mentorship, University of Nagoya, Nagoya, Japan, 11/1/2011
Advances in inflammatory breast cancer: Why is IBC clinical, translational, and basic research important for breast cancer research?, University of Montreal, Montreal, Canada, 1/11/2012

Lectureships and Visiting Professorships
Promotion of Multidisciplinary Care, Wakayama Oncology Symposium, Wakayama Oncology Symposium, Wakayama, Japan, 7/2006
Multidisciplinary Translational Research, Wakayama Oncology Symposium, Wakayama Oncology Symposium, Wakayama, Japan, 7/2007
Progress of Oncologic Multidisciplinary Care, Kobe University Graduate School, Kobe, Japan, 8/2008
Role of Allogeneic Transplantation in Solid Tumors, CCTS, University of Texas Medical School, Center for Clinical & Translation Sciences, Houston, TX, 5/28/2009
Preclinical development in Refractory Breast Cancer, Keio University, Tokyo, Japan, 10/19/2009
Visiting Professor, Wakaya Medical College, Oncology, Wakayama, Japan, 4/1/2010
Cancer Medicine and its future, Medical Topics, Waseda University, Tokyo, Japan, 10/27/2011

Guest Professor, Keio University School of Medicine, Tokyo, Japan, 4/1/2012

Advances in inflammatory breast cancer: Why is research on IBC important to research on all breast cancer?, Division of Cancer Medicine Grand Round, MD Anderson Cancer Center, Division of Cancer Medicine, Houston, TX, 6/19/2012

The power of one =Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, MD Anderson Cancer Center Grand Round, MD Anderson Cancer Center, Houston, TX, 6/22/2012

Other Presentations at State and Local Conferences

E1A as a tumor suppressor, Fifth annual radiation workshop at Round Top, Round Top, TX, 5/8/1997

Is there a role for high-dose chemotherapy with bone marrow rescue, Is there a role for high-dose chemotherapy with bone marrow rescue, M. D. Anderson Cancer Center, 2/14/2001

Advances in the Management of Breast Cancer, M. D. Anderson Cancer Center, M. D. Anderson Cancer Center, 6/2001

Renal Cell and Breast Cancer: current treatment options, BMT 2002: Stem Cells, Transplantation and the Therapy of Cancer – Update for Physicians and Case Management, M. D. Anderson Cancer Center, 2/2002

Development of biomarkers based on non-novel drugs, Ground Round, M. D. Anderson Cancer Center, Houston, TX, 3/2008

Yamauchi H, Iwata H, Nakamura S, Ueno NT. Epidemiology, characteristics, and outcomes of inflammatory breast cancer (IBC) in Japan, First International Inflammatory Breast Cancer Conference, The University of Texas M. D. Anderson Cancer Center, The University of Texas M. D. Anderson Cancer Center, Breast Medical Oncology, Houston, TX, 12/6/2008

Zhang D, LaFortune TA, Hortobagyi GN, Cristofanilli M, Lucci A, Singh B, Hung MC, Ueno NT. Reversal of mesenchymal to epithelial phenotype by EGFR tyrosine kinase inhibitor in inflammatory breast cancer, First International Inflammatory Breast Cancer Conference, The University of Texas M. D. Anderson Cancer Center, The University of Texas M. D. Anderson Cancer Center, Breast Medical Oncology, Houston, TX, 12/6/2008

Naoto Ueno. Role of Allogeneic Transplantation in Solid Tumors, The Center for Clinical and Translational Sciences, M. D. Anderson Cancer Center, Houston, TX, 5/28/2009

Effective Manuscript Writing, MD Anderson Cancer Center, The workshop Writing and Publishing Scientific Articles, Scientific Publication, Houston, TX, 10/20/2010

Ueno NT. Development of Novel Targeted Therapy in Inflammatory Breast Cancer, The University of Texas MD Anderson Cancer Center, Breast Cancer Research Program, Houston, TX, 4/9/2011

Ueno, NT. Advances in Inflammatory Breast Cancer, Physician Relations Grand Rounds, MD Anderson Cancer Center, Physicians Relations, Houston, TX, 2/22/2012

Apted J, Ueno NT. Being A Team Leader, GME Competency Lecture, The University of Texas MD Anderson Cancer Center, Trainee & Alumni Affairs, Houston, TX, 4/5/2012

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

Japan Comprehensive Cancer Network, Breast, Tokyo, Japan

Board of Directors, 2005–present

Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee, WI

Chair of Solid Tumor Working Committee, 3/2009–2/2014

Keio University School of Medicine Center for Clinical Cancer Research, Shinjuku, Japan

Visiting Professor, 5/2009–present

American Association for Cancer Research, PA

American Society of Blood and Marrow Transplantation

American Society of Clinical Oncology

American Society of Gene Therapy

American Society of Hematology

International Bone Marrow Transplant Registry

Local/State

UT Graduate School of Biomedical Sciences - Virology and Gene Therapy, Houston, TX

Member, 8/2000–present

UT Graduate School of Biomedical Sciences - Cancer Biology, Houston, TX

Member, 9/2000–present

UT Graduate School Biomedical Sciences Advisory Committee, Houston, TX
Member, 10/2007–present
Harris County Medical Society, Houston, TX

UNIQUE ACTIVITIES

1. Ueno NT, The need to change the patient's mindset. Nikkan-Yakugo Japanese Press (Daily Pharma), 7/2008.
2. Ueno NT, Hata T. Media clip Pharmacist & Patient 2008 Summer (07/2008) Cancer Care; Role of Pharmacists in Teamoncology. Page 1-4
3. Ueno NT, Doctor brings U.S. training home to Japanese patients. Kyodo News International, 7/2008.
4. Ueno NT, Doctor brings U.S. training home to Japanese patients. Japan Times, 7/2008.
5. Ueno NT, Need for patient to speak up to change the medical system. RIS FAX, Japanese Press (Pharma Economy), 7/2008.
6. Ueno NT, Need to change patient's mindset. Kyodo New American, 7/2008.
7. Book - "How to defend yourself from Breast cancer by diet and lifestyle." Author, Yuriko Oyabu; Published by Parade Publishing in Japan; Acknowledgement is found throughout the book to Dr. Ueno for providing data and discussing the book content. Published 2008
8. Third Breast Cancer Seminar in NY, BC Network, Yomitime, NY, USA, 10/08
9. Ueno, N, Protein forces ovarian cancer cells to eat themselves, Cancer Research UK news article, 11/19/2008
10. Ueno NT, Second Opinion by the Best Doctor. Avoiding side effect by selecting target in breast cancer. Weekly Asahi Magazine, 12/2008.
11. Practicing Multidisciplinary Care based on EBM Part I, Nikkei Medical Online, <http://medical.nikkeibp.co.jp/inc/all/search/cancer/>, 12/22/2008
12. Ueno NT. Konica Minolta Medical Network 2009, No. 1. Key Person.
13. Practicing Multidisciplinary Care based on EBM Part II, Nikkei Medical Online, <http://medical.nikkeibp.co.jp/inc/all/search/cancer/>, 01/2009
14. Ueno NT, TV Asahi, "Suikan no michi (Road to Survival)," 08/22/2009
15. Dream Team Oncology Program Press Conference on 03/19/10
16. Ueno, NT, Profiles in Oncology Social Media (4/25/10), Oncology Times, May 25, 2010, Vol. 32, No. 10.
17. Oncology Social Media Favorite Naoto Ueno (07/09/10), Oncology Times, July 10, 2010, Vol. 32, No. 13.
18. Invited to be a featured speaker for "TalkAboutHealth" which is a program with the social media where patients and caregivers get personalized, helpful, and accurate health answers from leading medical professionals and trained peer survivors. Featured Speaker in November 2011 and March 2012.
<http://talkabouthealth.com/static/aboutus>

DATE OF LAST CV UPDATE

7/10/2012

Naoto Tada Ueno, M.D., Ph.D., F.A.C.P.